<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Dermatopathology (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Dermatopathology (Basel)</journal-id><journal-id journal-id-type="publisher-id">dermatopathology</journal-id><journal-title-group><journal-title>Dermatopathology</journal-title></journal-title-group><issn pub-type="epub">2296-3529</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39982355</article-id><article-id pub-id-type="pmc">PMC11860556</article-id>
<article-id pub-id-type="doi">10.3390/dermatopathology12010007</article-id><article-id pub-id-type="publisher-id">dermatopathology-12-00007</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Pediatric Kikuchi&#x02013;Fujimoto Disease: Case Report and Review of Cutaneous and Histopathologic Features in Childhood</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5040-8483</contrib-id><name><surname>Soto-Moreno</surname><given-names>Alberto</given-names></name><xref rid="af1-dermatopathology-12-00007" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0014-2741</contrib-id><name><surname>V&#x000ed;lchez-M&#x000e1;rquez</surname><given-names>Francisco</given-names></name><xref rid="af1-dermatopathology-12-00007" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Narv&#x000e1;ez-Sim&#x000f3;n</surname><given-names>Mar&#x000ed;a</given-names></name><xref rid="af2-dermatopathology-12-00007" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Castro-Mart&#x000ed;n</surname><given-names>Julia</given-names></name><xref rid="af1-dermatopathology-12-00007" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0009-8829-7251</contrib-id><name><surname>Ramos-Pleguezuelos</surname><given-names>Francisco Manuel</given-names></name><xref rid="af2-dermatopathology-12-00007" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Soto-D&#x000ed;az</surname><given-names>Agust&#x000ed;n</given-names></name><xref rid="af1-dermatopathology-12-00007" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1548-594X</contrib-id><name><surname>Tercedor-S&#x000e1;nchez</surname><given-names>Jes&#x000fa;s</given-names></name><xref rid="af1-dermatopathology-12-00007" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4186-1435</contrib-id><name><surname>Arias-Santiago</surname><given-names>Salvador</given-names></name><xref rid="af1-dermatopathology-12-00007" ref-type="aff">1</xref><xref rid="af3-dermatopathology-12-00007" ref-type="aff">3</xref><xref rid="c1-dermatopathology-12-00007" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Kaya</surname><given-names>G&#x000fc;rkan</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-dermatopathology-12-00007"><label>1</label>Dermatology Department, Hospital Universitario Virgen de Las Nieves, 18012 Granada, Spain; <email>albertosotomoreno96@gmail.com</email> (A.S.-M.); <email>francisco.vilchez.marquez.sspa@juntadeandalucia.es</email> (F.V.-M.); <email>juliacastromart@gmail.com</email> (J.C.-M.); <email>agustin.soto.diaz@gmail.com</email> (A.S.-D.); <email>jesustercedor@gmail.com</email> (J.T.-S.)</aff><aff id="af2-dermatopathology-12-00007"><label>2</label>Pathology Derpartment, Hospital Universitario Virgen de Las Nieves, 18012 Granada, Spain<email>patologiafmrp@gmail.com</email> (F.M.R.-P.)</aff><aff id="af3-dermatopathology-12-00007"><label>3</label>Granada Institute for Biosanitary Research, 18012 Granada, Spain</aff><author-notes><corresp id="c1-dermatopathology-12-00007"><label>*</label>Correspondence: <email>salvadorarias@hotmail.es</email>; Tel.: +34-958-02-32-64</corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2025</year></pub-date><volume>12</volume><issue>1</issue><elocation-id>7</elocation-id><history><date date-type="received"><day>27</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>27</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>05</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Published by MDPI on behalf of the European Society of Dermatopathology. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Kikuchi&#x02013;Fujimoto disease (KFD) is a rare condition characterized by necrotizing lymphadenitis and fever, often associated with immune dysregulation. Histologically, it features necrotic foci with abundant histiocytes and plasmacytoid dendritic cells but notably lacks neutrophils and eosinophils. Recent evidence reveals a notable prevalence among pediatric patients, who may exhibit distinct features compared to adults. We reported the case of an 11-year-old girl presenting with persistent fever, cervical adenopathy, and a malar rash, leading to a diagnosis of KFD following lymph node biopsy, which revealed non-suppurative necrosis and histiocytic infiltration. Empirical treatment with antivirals and antibiotics was ineffective, but corticosteroid therapy achieved symptom remission. A literature review identified 48 relevant studies involving 386 pediatric cases, with histopathological findings consistent with classical descriptions of KFD. Cutaneous involvement was reported in 11.14% of cases, ranging from maculopapular rashes to lupus-like eruptions. Notable complications included the development of systemic lupus erythematous, Sj&#x000f6;gren syndrome, and rare instances of hemophagocytic syndrome or central nervous system involvement. Kikuchi&#x02013;Fujimoto disease should be considered in the differential diagnosis of pediatric patients presenting with fever and lymphadenopathy, taking into account a higher frequency of cutaneous manifestations in pediatric cases. A skin biopsy may be helpful in diagnosing KFD and provide valuable information regarding the potential risk of developing systemic lupus erythematosus in the future.</p></abstract><kwd-group><kwd>Kikuchi&#x02013;Fujimoto disease</kwd><kwd>children</kwd><kwd>histiocytic necrotizing lymphadenitis</kwd><kwd>lupus erythematosus</kwd><kwd>skin</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-dermatopathology-12-00007"><title>1. Introduction</title><p>Kikuchi&#x02013;Fujimoto disease (KFD) is a rare condition characterized by subacute necrotizing lymphadenopathy and fever [<xref rid="B1-dermatopathology-12-00007" ref-type="bibr">1</xref>,<xref rid="B2-dermatopathology-12-00007" ref-type="bibr">2</xref>]. Its etiology remains unknown, although an immune-mediated pathogenesis has been proposed [<xref rid="B2-dermatopathology-12-00007" ref-type="bibr">2</xref>]. This hypothesis could explain the association between KFD and systemic lupus erythematosus (SLE), which relatively frequently results in the coexistence of both conditions in the same patient [<xref rid="B2-dermatopathology-12-00007" ref-type="bibr">2</xref>].</p><p>Histologically, KFD is characterized by histiocytic necrosis with abundant karyorrhectic nuclear debris and a notable absence of neutrophils and eosinophils [<xref rid="B2-dermatopathology-12-00007" ref-type="bibr">2</xref>]. Immunohistochemistry (IHC) commonly reveals histiocytes that are myeloperoxidase-positive (MPO+) and CD68+, a predominance of T-cells within the lesions, and CD123+ plasmacytoid dendritic cells surrounding the necrotic areas [<xref rid="B1-dermatopathology-12-00007" ref-type="bibr">1</xref>,<xref rid="B2-dermatopathology-12-00007" ref-type="bibr">2</xref>,<xref rid="B3-dermatopathology-12-00007" ref-type="bibr">3</xref>].</p><p>Although KFD was initially thought to predominantly affect young adults, recent increases in reports of pediatric cases suggest that this condition is not as uncommon in childhood as previously believed [<xref rid="B4-dermatopathology-12-00007" ref-type="bibr">4</xref>,<xref rid="B5-dermatopathology-12-00007" ref-type="bibr">5</xref>,<xref rid="B6-dermatopathology-12-00007" ref-type="bibr">6</xref>]. Additionally, some studies have suggested differences between pediatric and adult cases, such as a higher prevalence of cutaneous rash in children [<xref rid="B4-dermatopathology-12-00007" ref-type="bibr">4</xref>]. In this study, we present a case of pediatric KFD and provide a literature review to enhance the understanding of this condition in children.</p></sec><sec id="sec2-dermatopathology-12-00007"><title>2. Case Report</title><sec id="sec2dot1-dermatopathology-12-00007"><title>2.1. Clinical Presentation</title><p>We present the case of an 11-year-old female admitted to the Department of Pediatrics with a persistent fever lasting more than a month, reaching temperatures up to 39 &#x000b0;C, and accompanied by a cervical adenopathic conglomerate. A similar episode had resulted in hospitalization the previous month, which had resolved with intravenous (IV) methylprednisolone.</p><p>During her hospital stay, she developed a rash characterized by erosive lesions and crusts located in the bilateral ciliary and malar regions, as well as on the lobes of both ears (<xref rid="dermatopathology-12-00007-f001" ref-type="fig">Figure 1</xref>). The patient was clinically diagnosed with Kaposi&#x02019;s varicelliform eruption, and a PCR test for herpes simplex virus was performed on the erosive lesions. Additionally, a complete blood count (CBC), autoimmunity panel, lymphocyte subpopulation analysis, and serology for multiple infectious agents were requested. An excisional biopsy of the cervical adenopathy and a punch biopsy of the skin were also conducted. Before a definitive clinical diagnosis was established, intravenous linezolid (600 mg/12 h) and acyclovir (10 mg/kg/8 h) were administered empirically but without significant clinical improvement.</p><p>PCR testing for viruses in the erosive lesions was negative. The CBC revealed leucopenia (2750/&#x000b5;L) and a slight increase in acute phase reactants. Serology tests for cytomegalovirus (CMV), Epstein&#x02013;Barr virus (EBV), human immunodeficiency virus (HIV), Hepatitis A, B, and C, Toxoplasma, Treponema, Bartonella, Brucella, and Leishmania were all negative. However, IgM antibodies against <italic toggle="yes">Mycoplasma pneumoniae</italic> were identified, along with positive antinuclear antibodies (ANAs) (speckled pattern, 1:160).</p><p>Although the skin biopsy demonstrated a nonspecific superficial perivascular lymphocytic infiltrate, the histological examination of the lymph node revealed findings consistent with non-suppurative necrotizing lymphadenitis with abundant histiocytes. Based on these results, a diagnosis of Kikuchi&#x02013;Fujimoto disease (KFD) was made. IV methylprednisolone (40 mg/day for 5 days) was administered, leading to the remission of both systemic and cutaneous symptoms. The patient was subsequently discharged on oral prednisone (30 mg/day with gradual tapering).</p><p>The patient is currently receiving hydroxychloroquine (200 mg/day) and remains under follow-up care with the pediatric dermatology department. One month after discharge, she has not experienced any recurrence of adenopathy or fever.</p></sec><sec id="sec2dot2-dermatopathology-12-00007"><title>2.2. Histopathologic Findings</title><p>The excisional biopsy revealed a lymph node measuring 1.3 &#x000d7; 1 cm, with a brownish surface and a typical nodular appearance.</p><p>Microscopically, the lymph node exhibited a distorted architecture, with residual lymphoid follicles observed in the cortex and expansion of the paracortical area (<xref rid="dermatopathology-12-00007-f002" ref-type="fig">Figure 2</xref>). Well-defined paracortical foci of non-suppurative necrosis with areas of karyorrhexis were identified. These foci were surrounded by an infiltrate composed of immunoblasts, plasma cells, histiocytes (<xref rid="dermatopathology-12-00007-f002" ref-type="fig">Figure 2</xref>B), abundant aggregates of CD123+ plasmacytoid dendritic cells (<xref rid="dermatopathology-12-00007-f002" ref-type="fig">Figure 2</xref>C), and lymphocytes predominantly expressing T-cell markers (CD3, CD2, CD5, CD7, CD4, and CD8). Sparse and occasionally scattered TdT-positive elements were also observed. No polymorphonuclear cells, eosinophils, or well-formed granulomas were identified.</p><p>Immunohistochemical markers assessed included CD20, Pax-5, CD79a, CD3, CD23, Bcl-6, Bcl-2, CD10, TdT, CD99, MUM-1, CD138, CD68, S100, CD1a, CD30, CD15, CD4, CD8, CD2, CD5, CD7, Ki-67, and CD123. Immunohistochemical staining for CMV was negative. The in situ hybridization study for the detection of EBV RNA was also negative. PAS, Giemsa, Grocott, and Warthin&#x02013;Starry stains, along with immunohistochemical staining for spirochetes, did not detect microorganisms in the examined sections.</p><p>The punch biopsy of the skin from the right eyelid area consisted of a 5 mm thick sample with a typical surface and included subcutaneous cellular tissue. Microscopically, a mild superficial chronic perivascular dermatitis was observed, without adnexal tropism, interface changes, basement membrane thickening, or interstitial mucin deposition (see <xref rid="dermatopathology-12-00007-f003" ref-type="fig">Figure 3</xref>). IHC was performed, showing no CD123-positive dendritic cells. An additional punch biopsy sample was submitted fresh for immunofluorescence study, which yielded negative results. The immunofluorescence panel included IgA, IgG, IgM, and C3.</p></sec></sec><sec id="sec3-dermatopathology-12-00007"><title>3. Literature Review</title><sec id="sec3dot1-dermatopathology-12-00007"><title>3.1. Methods</title><p>A bibliographic search was conducted in the Medline database through PubMed, using the following search strategy: &#x0201c;Kikuchi-Fujimoto disease&#x0201d; OR &#x0201c;Kikuchi&#x02019;s disease&#x0201d; OR &#x0201c;Necrotizing histiocytic lymphadenitis&#x0201d; AND (pediatric OR childhood OR children). A total of 225 results were identified. After reviewing titles and abstracts, 60 studies were selected. Three studies were excluded because they were reviews, two studies were excluded due to lack of access, and seven studies were excluded because they were not relevant to the research topic upon full-text review (see <xref rid="dermatopathology-12-00007-f004" ref-type="fig">Figure 4</xref>).</p></sec><sec id="sec3dot2-dermatopathology-12-00007"><title>3.2. Results</title><p>A total of 48 studies were included in the final analysis (see <xref rid="dermatopathology-12-00007-t001" ref-type="table">Table 1</xref>): 11 were retrospective observational studies, and 37 were case reports involving one or two cases. The studies included 386 patients (209 males, 163 females, and 14 of unspecified gender). The overall weighted mean age was 12.67 years.</p></sec><sec id="sec3dot3-dermatopathology-12-00007"><title>3.3. Cutaneous Manifestations</title><p>Skin manifestations were observed in approximately 11.14% of the sample. Generalized maculopapular rashes were reported in at least 40 patients [<xref rid="B7-dermatopathology-12-00007" ref-type="bibr">7</xref>,<xref rid="B8-dermatopathology-12-00007" ref-type="bibr">8</xref>,<xref rid="B9-dermatopathology-12-00007" ref-type="bibr">9</xref>,<xref rid="B10-dermatopathology-12-00007" ref-type="bibr">10</xref>,<xref rid="B11-dermatopathology-12-00007" ref-type="bibr">11</xref>,<xref rid="B12-dermatopathology-12-00007" ref-type="bibr">12</xref>,<xref rid="B13-dermatopathology-12-00007" ref-type="bibr">13</xref>,<xref rid="B14-dermatopathology-12-00007" ref-type="bibr">14</xref>], and other findings included plantar annular erythema, chilblain lupus-like rashes [<xref rid="B15-dermatopathology-12-00007" ref-type="bibr">15</xref>], and non-pruritic generalized rash, sparing the nasolabial folds [<xref rid="B16-dermatopathology-12-00007" ref-type="bibr">16</xref>]. Oral ulcers were reported in 13 patients [<xref rid="B13-dermatopathology-12-00007" ref-type="bibr">13</xref>,<xref rid="B17-dermatopathology-12-00007" ref-type="bibr">17</xref>]. The only case of malar rash concomitant with KFD developed lupus during follow-up [<xref rid="B18-dermatopathology-12-00007" ref-type="bibr">18</xref>].</p></sec><sec id="sec3dot4-dermatopathology-12-00007"><title>3.4. Histopathology</title><p>Most studies reported common histologic findings from excisional lymph node biopsy specimens, including cortical/paracortical necrosis, karyorrhexis, the presence of histiocytes (CD68+), plasmacytoid dendritic cells (CD123+), T-cell activation, and the absence of neutrophils, eosinophils, and granulomas (see <xref rid="dermatopathology-12-00007-t001" ref-type="table">Table 1</xref>). Lin et al. described the three histologic phenotypes of KFD: proliferative, necrotizing, and xanthomatous [<xref rid="B19-dermatopathology-12-00007" ref-type="bibr">19</xref>]. Camacho et al. identified organized granulomas in a lymph node specimen [<xref rid="B20-dermatopathology-12-00007" ref-type="bibr">20</xref>]. Skin punch biopsy was performed in only one case, revealing histologic findings of lymphohistiocytic infiltrates, predominantly perivascular, without necrosis of the adjacent vascular wall [<xref rid="B7-dermatopathology-12-00007" ref-type="bibr">7</xref>].</p></sec><sec id="sec3dot5-dermatopathology-12-00007"><title>3.5. Treatment</title><p>A significant number of cases were self-limiting and did not require specific treatment [<xref rid="B6-dermatopathology-12-00007" ref-type="bibr">6</xref>,<xref rid="B8-dermatopathology-12-00007" ref-type="bibr">8</xref>,<xref rid="B10-dermatopathology-12-00007" ref-type="bibr">10</xref>,<xref rid="B11-dermatopathology-12-00007" ref-type="bibr">11</xref>,<xref rid="B12-dermatopathology-12-00007" ref-type="bibr">12</xref>,<xref rid="B19-dermatopathology-12-00007" ref-type="bibr">19</xref>,<xref rid="B20-dermatopathology-12-00007" ref-type="bibr">20</xref>,<xref rid="B21-dermatopathology-12-00007" ref-type="bibr">21</xref>,<xref rid="B22-dermatopathology-12-00007" ref-type="bibr">22</xref>,<xref rid="B23-dermatopathology-12-00007" ref-type="bibr">23</xref>,<xref rid="B24-dermatopathology-12-00007" ref-type="bibr">24</xref>,<xref rid="B25-dermatopathology-12-00007" ref-type="bibr">25</xref>,<xref rid="B26-dermatopathology-12-00007" ref-type="bibr">26</xref>,<xref rid="B27-dermatopathology-12-00007" ref-type="bibr">27</xref>,<xref rid="B28-dermatopathology-12-00007" ref-type="bibr">28</xref>,<xref rid="B29-dermatopathology-12-00007" ref-type="bibr">29</xref>]. In severe cases, or those associated with hemophagocytic syndrome, the most frequently administered treatments were prednisone [<xref rid="B9-dermatopathology-12-00007" ref-type="bibr">9</xref>,<xref rid="B11-dermatopathology-12-00007" ref-type="bibr">11</xref>,<xref rid="B12-dermatopathology-12-00007" ref-type="bibr">12</xref>,<xref rid="B16-dermatopathology-12-00007" ref-type="bibr">16</xref>,<xref rid="B18-dermatopathology-12-00007" ref-type="bibr">18</xref>,<xref rid="B19-dermatopathology-12-00007" ref-type="bibr">19</xref>,<xref rid="B25-dermatopathology-12-00007" ref-type="bibr">25</xref>,<xref rid="B30-dermatopathology-12-00007" ref-type="bibr">30</xref>,<xref rid="B31-dermatopathology-12-00007" ref-type="bibr">31</xref>,<xref rid="B32-dermatopathology-12-00007" ref-type="bibr">32</xref>], and IV methylprednisolone sometimes combined with IV immunoglobulin [<xref rid="B9-dermatopathology-12-00007" ref-type="bibr">9</xref>,<xref rid="B14-dermatopathology-12-00007" ref-type="bibr">14</xref>,<xref rid="B33-dermatopathology-12-00007" ref-type="bibr">33</xref>,<xref rid="B34-dermatopathology-12-00007" ref-type="bibr">34</xref>,<xref rid="B35-dermatopathology-12-00007" ref-type="bibr">35</xref>,<xref rid="B36-dermatopathology-12-00007" ref-type="bibr">36</xref>,<xref rid="B37-dermatopathology-12-00007" ref-type="bibr">37</xref>,<xref rid="B38-dermatopathology-12-00007" ref-type="bibr">38</xref>,<xref rid="B39-dermatopathology-12-00007" ref-type="bibr">39</xref>]. Hydroxychloroquine was commonly used in cases associated with SLE or lupus-like rashes [<xref rid="B12-dermatopathology-12-00007" ref-type="bibr">12</xref>,<xref rid="B13-dermatopathology-12-00007" ref-type="bibr">13</xref>,<xref rid="B15-dermatopathology-12-00007" ref-type="bibr">15</xref>,<xref rid="B16-dermatopathology-12-00007" ref-type="bibr">16</xref>,<xref rid="B18-dermatopathology-12-00007" ref-type="bibr">18</xref>,<xref rid="B19-dermatopathology-12-00007" ref-type="bibr">19</xref>].</p></sec><sec id="sec3dot6-dermatopathology-12-00007"><title>3.6. Complications</title><p>A total of 10 cases of SLE were documented [<xref rid="B5-dermatopathology-12-00007" ref-type="bibr">5</xref>,<xref rid="B6-dermatopathology-12-00007" ref-type="bibr">6</xref>,<xref rid="B10-dermatopathology-12-00007" ref-type="bibr">10</xref>,<xref rid="B13-dermatopathology-12-00007" ref-type="bibr">13</xref>,<xref rid="B14-dermatopathology-12-00007" ref-type="bibr">14</xref>,<xref rid="B15-dermatopathology-12-00007" ref-type="bibr">15</xref>,<xref rid="B16-dermatopathology-12-00007" ref-type="bibr">16</xref>,<xref rid="B18-dermatopathology-12-00007" ref-type="bibr">18</xref>,<xref rid="B37-dermatopathology-12-00007" ref-type="bibr">37</xref>], with only two occurring concomitantly with KFD [<xref rid="B13-dermatopathology-12-00007" ref-type="bibr">13</xref>,<xref rid="B37-dermatopathology-12-00007" ref-type="bibr">37</xref>]. Additionally, four patients developed Sj&#x000f6;gren syndrome [<xref rid="B14-dermatopathology-12-00007" ref-type="bibr">14</xref>,<xref rid="B15-dermatopathology-12-00007" ref-type="bibr">15</xref>]. Among the reported complications, central nervous system involvement [<xref rid="B14-dermatopathology-12-00007" ref-type="bibr">14</xref>,<xref rid="B23-dermatopathology-12-00007" ref-type="bibr">23</xref>,<xref rid="B39-dermatopathology-12-00007" ref-type="bibr">39</xref>,<xref rid="B40-dermatopathology-12-00007" ref-type="bibr">40</xref>] and hemophagocytic syndrome [<xref rid="B9-dermatopathology-12-00007" ref-type="bibr">9</xref>,<xref rid="B14-dermatopathology-12-00007" ref-type="bibr">14</xref>,<xref rid="B33-dermatopathology-12-00007" ref-type="bibr">33</xref>,<xref rid="B41-dermatopathology-12-00007" ref-type="bibr">41</xref>] were particularly noteworthy.</p><table-wrap position="anchor" id="dermatopathology-12-00007-t001"><object-id pub-id-type="pii">dermatopathology-12-00007-t001_Table 1</object-id><label>Table 1</label><caption><p>Literature review. ANAs: antinuclear antibodies; CNS: central nervous system; CMV: cytomegalovirus; COVID-19: coronavirus disease 2019; EBV: Epstein&#x02013;Barr virus; IV: intravenous; IVIG: intravenous immunoglobulin; MTX: methotrexate; NA: not available; SLE: systemic lupus erythematosus; and SS: Sj&#x000f6;gren syndrome.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study<break/>(Date)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N; Sex; Age.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Histopathology </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cutaneous Manifestations</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Possible Trigger</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Associated Complications</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heldenberg et al. [<xref rid="B21-dermatopathology-12-00007" ref-type="bibr">21</xref>]<break/>1996</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; male; 10.</td><td rowspan="39" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Lymph node excisional biopsy</td><td rowspan="39" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Cortical or paracortical necrosis. Karyorrhexis. Histiocytes (CD68+), plasmacytoid dendritic cells (CD123+),<break/>T-cell activation. Absence of neutrophils, eosinophils and granulomas</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No specific<break/>therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gonz&#x000e1;lvez-Pi&#x000f1;era et al. [<xref rid="B8-dermatopathology-12-00007" ref-type="bibr">8</xref>]<break/>2000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; female; 7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generalized maculopapular rash</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No specific therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Emir et al. [<xref rid="B42-dermatopathology-12-00007" ref-type="bibr">42</xref>]<break/>2001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; female; 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No specific therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No<break/></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kim et al. [<xref rid="B9-dermatopathology-12-00007" ref-type="bibr">9</xref>]<break/>2003</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; female; 13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generalized maculopapular rash</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EBV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IVIG <break/>IV methylprednisolone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemophagocytic syndrome</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chiang et al. [<xref rid="B22-dermatopathology-12-00007" ref-type="bibr">22</xref>]<break/>2004</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; male; 8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No specific therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chuang et al. [<xref rid="B10-dermatopathology-12-00007" ref-type="bibr">10</xref>]<break/>2005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64; 35 males; 29 females;<break/>mean age 16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generalized maculopapular rash (4/64)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CMV<break/>(2/64)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No specific therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Developed SLE (1/64)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lin et al. [<xref rid="B6-dermatopathology-12-00007" ref-type="bibr">6</xref>]<break/>2005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23; 15 males; 8 females;<break/>mean age 12.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No specific therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Developed SLE (1/23)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Park et al. [<xref rid="B30-dermatopathology-12-00007" ref-type="bibr">30</xref>]<break/>2007</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16; 8 males; 8 females; mean age 10.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EBV (2) ANA (1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral prednisone (6/16)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zou et al. [<xref rid="B11-dermatopathology-12-00007" ref-type="bibr">11</xref>]<break/>2009</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36; 23 males; 13 females; mean age 10.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generalized maculopapular rash (5/36)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EBV (3/36)<break/>HSV (2/36)<break/>ANA (3/36)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No specific therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G&#x000f3;mez et al. [<xref rid="B31-dermatopathology-12-00007" ref-type="bibr">31</xref>]<break/>2010.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; female; 10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral prednisone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lee et al. [<xref rid="B5-dermatopathology-12-00007" ref-type="bibr">5</xref>]<break/>2012</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9; 8 males;1 female; mean age 11.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generalized maculopapular rash (2/9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No<break/>ANA (1/9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High-dose corticosteroids, IVIG, plasmapheresis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Developed SLE (1/9)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tchidjou et al. [<xref rid="B43-dermatopathology-12-00007" ref-type="bibr">43</xref>]<break/>2004</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; male; 11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV methylprednisolone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gon&#x000e7;alves et al. [<xref rid="B40-dermatopathology-12-00007" ref-type="bibr">40</xref>]<break/>2014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; male; 9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV Dexamethasone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CNS involvement</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Martins et al. [<xref rid="B18-dermatopathology-12-00007" ref-type="bibr">18</xref>]<break/>2014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; female; 12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">malar rash</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ANAs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral prednisone<break/>Hidroxychloroquine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Developed SLE</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ojeda et al. [<xref rid="B32-dermatopathology-12-00007" ref-type="bibr">32</xref>]<break/>2015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; female; 9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ANAs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral prednisone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rossetti et al. [<xref rid="B44-dermatopathology-12-00007" ref-type="bibr">44</xref>]<break/>2015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; male; 11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Corticosterois</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Upper airway obstruction</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Altinel et al. [<xref rid="B35-dermatopathology-12-00007" ref-type="bibr">35</xref>]<break/>2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; male; 12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Salmonella</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IVIG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Auto-immune thyroiditis and papilloedema</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chowdhury et al. [<xref rid="B39-dermatopathology-12-00007" ref-type="bibr">39</xref>]<break/>2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; female; 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV methylprednisolone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CNS involvement</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Handa et al. [<xref rid="B45-dermatopathology-12-00007" ref-type="bibr">45</xref>]<break/>2016</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; male; 15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral corticosteroids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lelii et al. [<xref rid="B23-dermatopathology-12-00007" ref-type="bibr">23</xref>]<break/>2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2; male; 12; female; 16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CMV (1/2)<break/>ANA (1/2)<break/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No specific<break/>therapy (1/2)<break/>Oral prednisone and cyclosporine (1/2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CNS involvement in 1 patient</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Singh et al. [<xref rid="B24-dermatopathology-12-00007" ref-type="bibr">24</xref>]<break/>2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; male; 11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No specific<break/>therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quadir et al. [<xref rid="B25-dermatopathology-12-00007" ref-type="bibr">25</xref>]<break/>2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2; females; 12 and 16<break/>(dizygotic twins)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generalized maculopapular rash (2/2)<break/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mycoplasma (1/2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No specific<break/>therapy (1/2)<break/>Oral prednisone (1/2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Developed alopecia areata<break/>(1/2)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Guleria et al. [<xref rid="B37-dermatopathology-12-00007" ref-type="bibr">37</xref>]<break/>2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6; 4 males; 2 females;<break/>mean age 10.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral prednisolone (2/6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Concomitant SLE (1/6)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arslan et al. [<xref rid="B46-dermatopathology-12-00007" ref-type="bibr">46</xref>]<break/>2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; female; 12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral prednisone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Optic Neuritis</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kim et al. [<xref rid="B26-dermatopathology-12-00007" ref-type="bibr">26</xref>]<break/>2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; female; 7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parvovirus B19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No specific<break/>Therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Severe neutropenia</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Al Mosawi et al. [<xref rid="B12-dermatopathology-12-00007" ref-type="bibr">12</xref>]<break/>2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11; 6 males; 5 females; mean age 10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generalized maculopapular rash (4/11)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hidroxychloroquine (7/11)<break/>Corticosteroids (1/11)<break/>No specific therapy (3/11)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cannon et al. [<xref rid="B27-dermatopathology-12-00007" ref-type="bibr">27</xref>]<break/>2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; female; 11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No specific<break/>therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hua et al. [<xref rid="B38-dermatopathology-12-00007" ref-type="bibr">38</xref>]<break/>2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; male; 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV methylprednisolone<break/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Appendectomy (mimicked appendicitis)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yang et al. [<xref rid="B14-dermatopathology-12-00007" ref-type="bibr">14</xref>]<break/>2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13; 9 males, 4 females</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generalized maculopapular rash in 10 patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ANAs in 4 patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IVIG + Methylprednisolone: (6/13)<break/>Methylprednisolone + Cyclosporine A: (1/13)<break/>Cyclosporine A + Dexamethasone + Etoposide: (1/13)<break/>Methylprednisolone + Cyclosporine A + Cyclophosphamide: (1/13)<break/>Ruxolitinib + Methylprednisolone: (1/13)<break/>Methylprednisolone + Dexamethasone: (1/13)<break/>Symptomatic treatment: (3/13)<break/>Intrathecal Injection + Methotrexate: (1/13)<break/>IV Immunoglobulin: (1/13)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemophagocytic syndrome (13/13)<break/>CNS involvement (8/13)<break/>Developed SLE (1/13)<break/>Developed SS (2/13)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Danai et al. [<xref rid="B13-dermatopathology-12-00007" ref-type="bibr">13</xref>]<break/>2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; female; 10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generalized maculopapular rash and oral ulcers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ANAs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prednisone Hidroxychloroquine<break/>Methotrexate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Concomitant SLE</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x000d6;zt&#x000fc;rk et al. [<xref rid="B47-dermatopathology-12-00007" ref-type="bibr">47</xref>] 2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; male; 5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No specific<break/>Therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chisholm et al. [<xref rid="B28-dermatopathology-12-00007" ref-type="bibr">28</xref>]<break/>2022</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14; NA; NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Takahashi et al. [<xref rid="B15-dermatopathology-12-00007" ref-type="bibr">15</xref>]<break/>2023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2;<break/>female, 13;<break/>male; 11<break/>brothers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plantar annular erythema and chilblain lupus-like rashes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No (later met the criteria for SLE)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Corticosteroid+ Hydroxychloroquine (1/2)<break/>Hydroxychloroquine (1/2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Developed SLE<break/>Developed SS (2/2)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sevrin et al. [<xref rid="B48-dermatopathology-12-00007" ref-type="bibr">48</xref>]<break/>2023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; male, 12<break/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19 vaccination</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Corticosterois</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Choi Sujin et al. [<xref rid="B17-dermatopathology-12-00007" ref-type="bibr">17</xref>]<break/>2023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">114; 62 males; 52 females; mean age 12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral ulcer (12/114)<break/>Generalized rash (11/114)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Corticosteroids (46/114)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zhou et al. [<xref rid="B49-dermatopathology-12-00007" ref-type="bibr">49</xref>]<break/>2024</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; male; 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral prednisone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CASPR2 antibody-associated encephalitis</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lu et al. [<xref rid="B50-dermatopathology-12-00007" ref-type="bibr">50</xref>]<break/>2024</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; male; 13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Corticosterois<break/>Rituximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">occlusive retinal vasculitis with near total central retinal artery occlusion </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bao et al. [<xref rid="B36-dermatopathology-12-00007" ref-type="bibr">36</xref>]<break/>2024</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; male; 13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IVIG,<break/>Oral prednisone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Optic Neuritis<break/></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Harrison et al. [<xref rid="B16-dermatopathology-12-00007" ref-type="bibr">16</xref>]<break/>2024</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; female; 16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generalized rash, sparing the nasolabial folds.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No (later met the criteria for SLE)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydroxychloroquine, prednisone, and mycophenolate mofetil<break/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Developed SLE<break/></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Camacho-Badilla et al. [<xref rid="B20-dermatopathology-12-00007" ref-type="bibr">20</xref>]<break/>2005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; male; 10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lymph node excisional biopsy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Granulomas characterized by central necrosis with abundant karyorrhexis, surrounded by histiocytes, lymphocytes and giant multinucleated cells, without neutrophils</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No specific<break/>therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Burns et al. [<xref rid="B29-dermatopathology-12-00007" ref-type="bibr">29</xref>]<break/>2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; female; 16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FNAC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Necrotizing lymphadenitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EBV, CMV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No specific<break/>therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sierra et al. [<xref rid="B7-dermatopathology-12-00007" ref-type="bibr">7</xref>]<break/>1999</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; male; 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1. Lymph node excisional biopsy<break/>2. Cutenaous biopsy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1. Histiocytic necrotizing lymphadenitis (see previous)<break/>2. Lymphohistiocytic infiltrates, predominantly perivascular, without any necrosis of the adjacent vascular wall</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generalized maculopapular rash</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV Methylprednisolone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multisystemic involvement<break/>Adverse reaction to drugs</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chen et al. [<xref rid="B33-dermatopathology-12-00007" ref-type="bibr">33</xref>]<break/>2000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; female; 13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1. Lymph node excisional biopsy<break/>2. Bone marrow aspirate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1. Histiocytic necrotizing lymphadenitis (see previous)<break/>2.hemophagocytic histiocytes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EBV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IVIG <break/>IV methylprednisolone<break/>oral dexamethasone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hemophagocytic syndrome</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Jun-Fen et al. [<xref rid="B34-dermatopathology-12-00007" ref-type="bibr">34</xref>]<break/>2007.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; female; 7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1. Lymph node excisional biopsy<break/>2. Bone marrow aspirate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1. Histiocytic necrotizing lymphadenitis (see previous)<break/>2. Specific Changes In idiopathic thrombocytopenic purpura</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IVIG <break/>IV methylprednisolone<break/>Oral dexamethasone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Idiopathic thrombocytopenic purpura and Mobitz type II atrioventricular block</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sykes et al. [<xref rid="B41-dermatopathology-12-00007" ref-type="bibr">41</xref>]<break/>2016</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; female; 26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1. Lymph node excisional biopsy<break/>2. Bone marrow aspirate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1. Cortical or paracortical necrosis with various histiocytes, plasmacytoid monocytes and a variable number of lymphoid cells with caryorrhectic nuclear fragments and absence of neutrophils<break/>2. hemophagocytic histiocytes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High-dose corticosteroids, IVIG, and plasmapheresis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemophagocytic syndrome</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Das et al. [<xref rid="B51-dermatopathology-12-00007" ref-type="bibr">51</xref>]<break/>2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; male; NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1. Lymph node excisional biopsy<break/>2. Bone marrow aspirate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1. Cortical or paracortical necrosis with various histiocytes, plasmacytoid monocytes and a variable number of lymphoid cells with caryorrhectic nuclear fragments and absence of neutrophils<break/>2. Reticulo-endothelial activity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generalized maculopapular rash</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brucella</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifampicin and gentamicin, doxycycline, trimethoprim-sulfamethoxazole.<break/>Oral prednisolone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxycycline-induced intracranial hypertension</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lin et al. [<xref rid="B19-dermatopathology-12-00007" ref-type="bibr">19</xref>]<break/>2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40; 20 males; 20 females; mean age 13.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lymph node excisional biopsy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 patients with proliferative type containing karyorrhectic nuclear fragments, eosinophilic apoptotic debris and various histiocytes<break/>23 patients with necrotizing type showing the existence of coagulative necrosis<break/>1 patient with xanthomatous type showing foamy histiocytes.<break/>2 patients with NA histopathology</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generalized maculopapular rash (2/40)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ANAs (1/40)<break/>EBV (1/40)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral prednisone (5/40)<break/>Hidroxychloroquine (5/40)<break/>No specific<break/>therapy in the rest</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abdu et al. [<xref rid="B52-dermatopathology-12-00007" ref-type="bibr">52</xref>]<break/>2022</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1; female, 10<break/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1. Lymph node excisionalbiopsy<break/>2. Bone marrow biopsy<break/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1. Necrotizing his- tiocytic lymphadenitis<break/>2. Normocellular bone marrow with reactive lymphocytosis and hemophagocytosis<break/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acute otitis media</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Corticosterois</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion" id="sec4-dermatopathology-12-00007"><title>4. Discussion</title><p>The currently available literature supports the notion that KFD is not an uncommon condition in childhood. Our case can be considered epidemiologically typical, as it occurs in a female under 30 years of age. While earlier studies suggested a female predominance, more recent research indicates that the incidence of KFD is similar between males and females [<xref rid="B1-dermatopathology-12-00007" ref-type="bibr">1</xref>,<xref rid="B53-dermatopathology-12-00007" ref-type="bibr">53</xref>]. Based on our review of pediatric cases, a higher proportion of males has been reported. This male predominance in pediatric cases has also been described in other series not included in this review [<xref rid="B4-dermatopathology-12-00007" ref-type="bibr">4</xref>].</p><p>Cutaneous manifestations associated with KFD have been described as more frequent in children, with an incidence of approximately 10% [<xref rid="B4-dermatopathology-12-00007" ref-type="bibr">4</xref>], consistent with the findings in our review. These manifestations typically present as a maculopapular rash, predominantly on the face and the upper trunk. However, a wide range of dermatoses has been documented, including urticarial, morbilliform, rubella-like, lupus-like, or drug-eruption-like rashes; facial erythema; generalized erythema; papules, plaques, and nodules; leukocytoclastic vasculitis; erythema multiforme; papulopustules; and even eyelid edema [<xref rid="B54-dermatopathology-12-00007" ref-type="bibr">54</xref>,<xref rid="B55-dermatopathology-12-00007" ref-type="bibr">55</xref>,<xref rid="B56-dermatopathology-12-00007" ref-type="bibr">56</xref>]. The histopathology of cutaneous lesions in KFD is similarly diverse. Specific findings associated with extranodal KFD include an infiltrate composed of lymphocytes, histiocytes, plasmacytoid monocytes, and nuclear debris, notably in the absence of neutrophils [<xref rid="B55-dermatopathology-12-00007" ref-type="bibr">55</xref>,<xref rid="B57-dermatopathology-12-00007" ref-type="bibr">57</xref>]. Occasionally, the histology resembles the cutaneous features of SLE, showing interface changes with the vacuolar degeneration of basal cells, necrotic keratynocites and mild perivascular infiltrates of lymphocytes and histiocytes in skin biopsies [<xref rid="B54-dermatopathology-12-00007" ref-type="bibr">54</xref>,<xref rid="B58-dermatopathology-12-00007" ref-type="bibr">58</xref>]. In any case, the overlap of histologic findings has made it challenging for dermatopathologists to classify a skin biopsy as either extranodal KFD or SLE. In a series of 16 KFD cases with skin biopsy, Kim et al. used direct immunofluorescence negativity and the absence of plasma cells as the primary criteria to rule out SLE [<xref rid="B57-dermatopathology-12-00007" ref-type="bibr">57</xref>]. It has been suggested that interface changes observed in skin biopsies may predict an increased risk of developing SLE [<xref rid="B59-dermatopathology-12-00007" ref-type="bibr">59</xref>]. This study is based on 10 cases of KFD with cutaneous manifestations and skin biopsy, all of which subsequently developed SLE, with interface dermatitis observed in each biopsy. However, the same authors acknowledge that this statement is not entirely consistent, citing three cases of KFD with interface dermatitis on skin biopsy that did not progress to SLE [<xref rid="B59-dermatopathology-12-00007" ref-type="bibr">59</xref>].</p><p>Our case presented malar erosive lesions typically affecting the ears, resembling those described in other case reports involving both pediatric and adult patients [<xref rid="B60-dermatopathology-12-00007" ref-type="bibr">60</xref>,<xref rid="B61-dermatopathology-12-00007" ref-type="bibr">61</xref>]. Histologically, no sufficient evidence of extranodal KFD or SLE was identified; instead, the biopsy revealed a superficial perivascular lymphocytic infiltrate without interface changes. The limited findings in the skin biopsy may be attributed to the location near the eyelid of the sample, chosen to minimize the aesthetic impact of scarring in an area where the erosive component was minimal. Nevertheless, non-specific perivascular dermatitis is a common finding in skin biopsies of patients with KFD [<xref rid="B7-dermatopathology-12-00007" ref-type="bibr">7</xref>,<xref rid="B62-dermatopathology-12-00007" ref-type="bibr">62</xref>]. Lupus-like rash appears to predict a higher risk of developing SLE. This, combined with the presence of ANAs in the patient&#x02019;s analysis, prompted the initiation of hydroxychloroquine therapy and the establishment of close follow-up.</p><p>Fine needle aspiration of the lymph node does not seem to provide a sufficient sample for diagnosis [<xref rid="B2-dermatopathology-12-00007" ref-type="bibr">2</xref>], although it was the technique used in one of the cases in our review [<xref rid="B29-dermatopathology-12-00007" ref-type="bibr">29</xref>]. In general, the excisional biopsy of a lymph node is recommended for the diagnosis of KFD. The histopathologic findings of the lymph node biopsy, both in the case presented and in most of the pediatric cases reviewed, are consistently similar: cortical or paracortical necrosis, karyorrhexis, histiocytes (MPO+, CD68+), plasmacytoid dendritic cells (CD123+), and T-cell activation. Notably, there is an absence of neutrophils, eosinophils, and granulomas. Histopathologically, three chronologically related stages of KFD have been described [<xref rid="B1-dermatopathology-12-00007" ref-type="bibr">1</xref>,<xref rid="B2-dermatopathology-12-00007" ref-type="bibr">2</xref>]. Initially, the proliferative stage is characterized by follicular hyperplasia and lymphohistiocytic infiltrates [<xref rid="B1-dermatopathology-12-00007" ref-type="bibr">1</xref>,<xref rid="B2-dermatopathology-12-00007" ref-type="bibr">2</xref>]. During the necrotizing stage, karyorrhexis and necrosis artifacts become evident, while the lymph node architecture remains intact [<xref rid="B1-dermatopathology-12-00007" ref-type="bibr">1</xref>,<xref rid="B2-dermatopathology-12-00007" ref-type="bibr">2</xref>]. Finally, in the xanthomatous stage, foamy histiocytes are observed as the necrotic areas regress [<xref rid="B1-dermatopathology-12-00007" ref-type="bibr">1</xref>,<xref rid="B2-dermatopathology-12-00007" ref-type="bibr">2</xref>]. Based on these stages, it can be inferred that most pediatric cases presented findings consistent with the proliferative and necrotizing phases, although this distinction was not explicitly made by the authors. Only Lin et al. classified their findings according to these phenotypes, reporting 14 patients with the proliferative type, 23 with the necrotizing type, and 1 with the xanthomatous type [<xref rid="B19-dermatopathology-12-00007" ref-type="bibr">19</xref>]. In summary, the histologic findings of lymph node biopsies in pediatric KFD are similar to those observed in adults.</p><p>An acute <italic toggle="yes">M. pneumoniae</italic> infection may have triggered the clinical presentation in our patient. Other pediatric and adult cases have also identified this infectious agent as a potential trigger [<xref rid="B25-dermatopathology-12-00007" ref-type="bibr">25</xref>,<xref rid="B63-dermatopathology-12-00007" ref-type="bibr">63</xref>,<xref rid="B64-dermatopathology-12-00007" ref-type="bibr">64</xref>]. Additional agents including <italic toggle="yes">Yersinia</italic>, <italic toggle="yes">Toxoplasma</italic>, EBV, human herpes virus 6 and 8, human T-lymphotropic virus type 1, and parvovirus B19 have been implicated as possible causes, though these associations remain unconfirmed [<xref rid="B1-dermatopathology-12-00007" ref-type="bibr">1</xref>,<xref rid="B2-dermatopathology-12-00007" ref-type="bibr">2</xref>]. However, the majority of reviewed cases were idiopathic.</p><p>KFD is typically a self-limiting condition unless complications arise [<xref rid="B1-dermatopathology-12-00007" ref-type="bibr">1</xref>,<xref rid="B2-dermatopathology-12-00007" ref-type="bibr">2</xref>]. Antibiotics are frequently administered prior to a definitive diagnosis, as occurred in our case [<xref rid="B1-dermatopathology-12-00007" ref-type="bibr">1</xref>,<xref rid="B2-dermatopathology-12-00007" ref-type="bibr">2</xref>]. The use of IV immunoglobulin and methylprednisolone appears justified in severe cases, such as those involving CNS complications or hemophagocytic syndrome [<xref rid="B9-dermatopathology-12-00007" ref-type="bibr">9</xref>,<xref rid="B14-dermatopathology-12-00007" ref-type="bibr">14</xref>,<xref rid="B33-dermatopathology-12-00007" ref-type="bibr">33</xref>,<xref rid="B34-dermatopathology-12-00007" ref-type="bibr">34</xref>,<xref rid="B35-dermatopathology-12-00007" ref-type="bibr">35</xref>,<xref rid="B36-dermatopathology-12-00007" ref-type="bibr">36</xref>,<xref rid="B37-dermatopathology-12-00007" ref-type="bibr">37</xref>,<xref rid="B38-dermatopathology-12-00007" ref-type="bibr">38</xref>,<xref rid="B39-dermatopathology-12-00007" ref-type="bibr">39</xref>]. Similarly, hydroxychloroquine has been employed in cases with concomitant SLE or those at high risk of developing it (12,13,15,16,18,1). Nonetheless, clinical trial data remain insufficient to fully validate these therapeutic approaches.</p><p>Considering the clinical manifestations, the differential diagnosis of KFD is broad due to the nonspecific nature of its symptoms [<xref rid="B1-dermatopathology-12-00007" ref-type="bibr">1</xref>,<xref rid="B28-dermatopathology-12-00007" ref-type="bibr">28</xref>]. On one hand, infectious agents could be responsible for lymphadenitis and fever [<xref rid="B1-dermatopathology-12-00007" ref-type="bibr">1</xref>,<xref rid="B28-dermatopathology-12-00007" ref-type="bibr">28</xref>,<xref rid="B57-dermatopathology-12-00007" ref-type="bibr">57</xref>]. On the other hand, immune-mediated diseases, particularly SLE, could explain the systemic and cutaneous findings [<xref rid="B1-dermatopathology-12-00007" ref-type="bibr">1</xref>,<xref rid="B28-dermatopathology-12-00007" ref-type="bibr">28</xref>,<xref rid="B57-dermatopathology-12-00007" ref-type="bibr">57</xref>]. In fact, the concurrent or sequential occurrence of KFD and SLE has been frequently reported. Therefore, ruling out SLE in patients with compatible clinical features or a confirmed diagnosis of KFD is imperative [<xref rid="B16-dermatopathology-12-00007" ref-type="bibr">16</xref>,<xref rid="B59-dermatopathology-12-00007" ref-type="bibr">59</xref>,<xref rid="B64-dermatopathology-12-00007" ref-type="bibr">64</xref>]. Additionally, oncologic and hematologic processes (Classical Hodgkin lymphoma, B-cell or T-cell non-Hodgkin lymphomas, myeloid sarcoma) could account for lymphadenopathy and nonspecific systemic symptoms in pediatric patients [<xref rid="B1-dermatopathology-12-00007" ref-type="bibr">1</xref>,<xref rid="B22-dermatopathology-12-00007" ref-type="bibr">22</xref>,<xref rid="B28-dermatopathology-12-00007" ref-type="bibr">28</xref>,<xref rid="B57-dermatopathology-12-00007" ref-type="bibr">57</xref>]. In our case, testing for most infectious agents (CMV, EBV, HIV, HAV&#x02026;), both in blood and in lymph node samples, returned negative results, except for acute infection with <italic toggle="yes">M. pneumoniae</italic>, which, as previously discussed, may have acted as a triggering factor. The autoimmune findings in our patient, while not sufficient to diagnose concomitant SLE and KFD, do raise the possibility of the future development of SLE. This potential progression justified the initiation of hydroxychloroquine therapy and periodic follow-up. Finally, the possibility of an oncologic or hematologic process, which warranted excisional biopsy of the lymph node, was excluded after histological and immunohistochemical analysis of the specimen.</p><p>Considering the histological findings, differentiating KFD from SLE lymphadenopathy is challenging due to overlapping features like the paracortical necrosis and absence of neutrophils [<xref rid="B1-dermatopathology-12-00007" ref-type="bibr">1</xref>]. Specific findings in SLE lymphadenopathy include hematoxylin bodies, composed of polysaccharides, immunoglobulins, and nuclear debris [<xref rid="B65-dermatopathology-12-00007" ref-type="bibr">65</xref>,<xref rid="B66-dermatopathology-12-00007" ref-type="bibr">66</xref>]. The Azzopardi phenomenon, with hematoxylin-stained nuclear material in blood vessels within necrotic areas, can also aid in diagnosis [<xref rid="B65-dermatopathology-12-00007" ref-type="bibr">65</xref>,<xref rid="B66-dermatopathology-12-00007" ref-type="bibr">66</xref>]. Multiple infectious agents can cause necrotizing lymphadenitis. However, bacterial infections like Yersinia enterocolitica are characterized by abundant neutrophils, while tuberculosis, histoplasmosis, and cat-scratch disease typically show epithelioid histiocyte proliferation with granuloma formation [<xref rid="B1-dermatopathology-12-00007" ref-type="bibr">1</xref>,<xref rid="B67-dermatopathology-12-00007" ref-type="bibr">67</xref>]. Infectious mononucleosis often displays marked follicular hyperplasia, paracortical expansion, and increased immunoblasts, with scattered Hodgkin- and Reed-Sternberg-like cells [<xref rid="B68-dermatopathology-12-00007" ref-type="bibr">68</xref>]. Histologic findings require correlation with serologic and molecular testing for accurate diagnosis [<xref rid="B1-dermatopathology-12-00007" ref-type="bibr">1</xref>]. Immunohistochemistry can aid in differentiating KFD from lymphomas [<xref rid="B1-dermatopathology-12-00007" ref-type="bibr">1</xref>] but should never replace the hematoxylin and eosin evaluation of an adequate sample, as MPO positivity could be misinterpreted as myeloid sarcoma [<xref rid="B69-dermatopathology-12-00007" ref-type="bibr">69</xref>].</p><p>It remains necessary to address the differential diagnosis of the cutaneous findings. While maculopapular rash is a common, nonspecific feature in drug- or virus-related eruptions, the predominantly malar distribution and the erosive elements in our patient initially suggested a diagnosis of eczema herpeticum or SLE. However, the absence of cytopathic features and negative molecular studies ruled out eczema herpeticum, and the lack of histologic findings consistent with SLE in H-E staining, IHC and direct immunofluorescence ruled out this diagnosis. Vacuolar degeneration is frequently observed in skin samples from KFD patients, expanding the histopathologic differential diagnosis to papulosquamous disorders, such as pityriasis lichenoides et varioliformis acuta (PLEVA). Nevertheless, PLEVA is typically accompanied by neutrophils and rarely by histiocytes [<xref rid="B70-dermatopathology-12-00007" ref-type="bibr">70</xref>]. Given the focus of this manuscript on pediatric cases, Kawasaki disease should also be considered. Although it could justify part of the clinic, histologic findings in this condition include vasculitis, psoriasiform dermatitis, and interface changes resembling erythema multiforme [<xref rid="B71-dermatopathology-12-00007" ref-type="bibr">71</xref>]. The absence of neutrophils in the infiltrate excluded conditions that could explain the clinical manifestations, such as acute febrile neutrophilic dermatosis and bacterial soft tissue infections [<xref rid="B57-dermatopathology-12-00007" ref-type="bibr">57</xref>].</p><p>The present case provides results consistent with an extensive literature review of reported cases. However, some articles lacked detailed descriptions of histological findings, limiting the ability to identify KFD subtypes. The absence of follow-up in certain studies may have led to an underestimation of immune-mediated diseases associated with KFD. Additionally, a lack of specific dermatological examinations in some cases has diminished the value of findings related to cutaneous manifestations.</p><p>In conclusion, KFD should be considered in the differential diagnosis of persistent fever and lymphadenopathy in pediatric patients, as cutaneous manifestations are common, often presenting as maculopapular rashes. An excisional biopsy of a lymph node is essential for a definitive diagnosis, though a skin biopsy can provide valuable diagnostic information and help identify patients at risk of developing SLE.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Institutional Review Board Statement</title><p>The participants in this study provided informed consent for the dissemination of information and images for scientific purposes in the presentation of the clinical case. The remaining information described is derived from bibliographic sources available in the literature, presented in an anonymized form, and approved by the pertinent ethics committee.</p></notes><notes><title>Informed Consent Statement</title><p>The participants in this manuscript gave informed consent for publication of the details of their cases.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data supporting the conclusions of this study are available upon request from the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-dermatopathology-12-00007"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Perry</surname><given-names>A.M.</given-names></name>
<name><surname>Choi</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto Disease: A Review</article-title><source>Arch. Pathol. Lab. Med.</source><year>2018</year><volume>142</volume><fpage>1341</fpage><lpage>1346</lpage><pub-id pub-id-type="doi">10.5858/arpa.2018-0219-RA</pub-id><pub-id pub-id-type="pmid">30407860</pub-id>
</element-citation></ref><ref id="B2-dermatopathology-12-00007"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Masab</surname><given-names>M.</given-names></name>
<name><surname>Surmachevska</surname><given-names>N.</given-names></name>
<name><surname>Farooq</surname><given-names>H.</given-names></name>
</person-group><source>Kikuchi-Fujimoto Disease</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2024</year></element-citation></ref><ref id="B3-dermatopathology-12-00007"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cuglievan</surname><given-names>B.</given-names></name>
<name><surname>Miranda</surname><given-names>R.N.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto disease</article-title><source>Blood</source><year>2017</year><volume>129</volume><fpage>917</fpage><pub-id pub-id-type="doi">10.1182/blood-2016-08-736413</pub-id><pub-id pub-id-type="pmid">28209753</pub-id>
</element-citation></ref><ref id="B4-dermatopathology-12-00007"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>T.Y.</given-names></name>
<name><surname>Ha</surname><given-names>K.-S.</given-names></name>
<name><surname>Kim</surname><given-names>Y.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>K.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
</person-group><article-title>Characteristics of Kikuchi-Fujimoto disease in children compared with adults</article-title><source>Eur. J. Pediatr.</source><year>2014</year><volume>173</volume><fpage>111</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1007/s00431-013-2131-3</pub-id><pub-id pub-id-type="pmid">23955486</pub-id>
</element-citation></ref><ref id="B5-dermatopathology-12-00007"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>B.C.</given-names></name>
<name><surname>Patel</surname><given-names>R.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto disease: A 15-year analysis at a children&#x02019;s hospital in the United States</article-title><source>Clin. Pediatr.</source><year>2013</year><volume>52</volume><fpage>92</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1177/0009922811436338</pub-id><pub-id pub-id-type="pmid">22315483</pub-id>
</element-citation></ref><ref id="B6-dermatopathology-12-00007"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>H.-C.</given-names></name>
<name><surname>Su</surname><given-names>C.-Y.</given-names></name>
<name><surname>Huang</surname><given-names>S.-C.</given-names></name>
</person-group><article-title>Kikuchi&#x02019;s disease in Asian children</article-title><source>Pediatrics</source><year>2005</year><volume>115</volume><fpage>e92</fpage><lpage>e96</lpage><pub-id pub-id-type="doi">10.1542/peds.2004-0924</pub-id><pub-id pub-id-type="pmid">15629971</pub-id>
</element-citation></ref><ref id="B7-dermatopathology-12-00007"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sierra</surname><given-names>M.L.</given-names></name>
<name><surname>Vegas</surname><given-names>E.</given-names></name>
<name><surname>Blanco-Gonz&#x000e1;lez</surname><given-names>J.E.</given-names></name>
<name><surname>Gonz&#x000e1;lez</surname><given-names>A.</given-names></name>
<name><surname>Mart&#x000ed;nez</surname><given-names>P.</given-names></name>
<name><surname>Calero</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Kikuchi&#x02019;s disease with multisystemic involvement and adverse reaction to drugs</article-title><source>Pediatrics</source><year>1999</year><volume>104</volume><fpage>e24</fpage><pub-id pub-id-type="doi">10.1542/peds.104.2.e24</pub-id><pub-id pub-id-type="pmid">10454846</pub-id>
</element-citation></ref><ref id="B8-dermatopathology-12-00007"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gonz&#x000e1;lvez Pi&#x000f1;era</surname><given-names>J.</given-names></name>
<name><surname>Ruiz Cano</surname><given-names>R.</given-names></name>
<name><surname>Garc&#x000ed;a Rodr&#x000ed;guez</surname><given-names>M.R.</given-names></name>
<name><surname>Fern&#x000e1;ndez C&#x000f3;rdoba</surname><given-names>M.S.</given-names></name>
<name><surname>Crusat Bra&#x000f1;a</surname><given-names>S.</given-names></name>
<name><surname>Sango Lamban</surname><given-names>M.</given-names></name>
</person-group><article-title>Necrotizing histiocytic lymphadenitis (Kikuchi-Fujimoto disease) in a 7-year-old girl</article-title><source>Cir. Pediatr.</source><year>2000</year><volume>13</volume><fpage>126</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">12601944</pub-id>
</element-citation></ref><ref id="B9-dermatopathology-12-00007"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>Y.M.</given-names></name>
<name><surname>Lee</surname><given-names>Y.J.</given-names></name>
<name><surname>Nam</surname><given-names>S.O.</given-names></name>
<name><surname>Park</surname><given-names>S.E.</given-names></name>
<name><surname>Kim</surname><given-names>J.Y.</given-names></name>
<name><surname>Lee</surname><given-names>E.Y.</given-names></name>
</person-group><article-title>Hemophagocytic syndrome associated with Kikuchi&#x02019;s disease</article-title><source>J. Korean Med. Sci.</source><year>2003</year><volume>18</volume><fpage>592</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.3346/jkms.2003.18.4.592</pub-id><pub-id pub-id-type="pmid">12923340</pub-id>
</element-citation></ref><ref id="B10-dermatopathology-12-00007"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chuang</surname><given-names>C.-H.</given-names></name>
<name><surname>Yan</surname><given-names>D.-C.</given-names></name>
<name><surname>Chiu</surname><given-names>C.-H.</given-names></name>
<name><surname>Huang</surname><given-names>Y.-C.</given-names></name>
<name><surname>Lin</surname><given-names>P.-Y.</given-names></name>
<name><surname>Chen</surname><given-names>C.-J.</given-names></name>
<name><surname>Yen</surname><given-names>M.-H.</given-names></name>
<name><surname>Kuo</surname><given-names>T.-T.</given-names></name>
<name><surname>Lin</surname><given-names>T.-Y.</given-names></name>
</person-group><article-title>Clinical and laboratory manifestations of Kikuchi&#x02019;s disease in children and differences between patients with and without prolonged fever</article-title><source>Pediatr. Infect. Dis. J.</source><year>2005</year><volume>24</volume><fpage>551</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1097/01.inf.0000167246.24500.21</pub-id><pub-id pub-id-type="pmid">15933568</pub-id>
</element-citation></ref><ref id="B11-dermatopathology-12-00007"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zou</surname><given-names>C.C.</given-names></name>
<name><surname>Zhao</surname><given-names>Z.Y.</given-names></name>
<name><surname>Liang</surname><given-names>L.</given-names></name>
</person-group><article-title>Childhood Kikuchi-Fujimoto disease</article-title><source>Indian. J. Pediatr.</source><year>2009</year><volume>76</volume><fpage>959</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1007/s12098-009-0194-y</pub-id><pub-id pub-id-type="pmid">19904514</pub-id>
</element-citation></ref><ref id="B12-dermatopathology-12-00007"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al Mosawi</surname><given-names>Z.</given-names></name>
<name><surname>Ebrahim</surname><given-names>B.</given-names></name>
<name><surname>Baik</surname><given-names>S.</given-names></name>
<name><surname>Madan</surname><given-names>W.</given-names></name>
<name><surname>Aljufairi</surname><given-names>E.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto Disease: Eleven Pediatric Cases and Literature Review</article-title><source>Arch. Rheumatol.</source><year>2020</year><volume>35</volume><fpage>303</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.46497/ArchRheumatol.2020.7646</pub-id><pub-id pub-id-type="pmid">32851384</pub-id>
</element-citation></ref><ref id="B13-dermatopathology-12-00007"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Danai</surname><given-names>M.M.</given-names></name>
<name><surname>Kaye</surname><given-names>S.P.</given-names></name>
<name><surname>Gong</surname><given-names>R.</given-names></name>
<name><surname>McKnight</surname><given-names>H.</given-names></name>
</person-group><article-title>A Rare Pediatric Case of Persistent Kikuchi-Fujimoto Disease and Underlying Systemic Lupus Erythematosus</article-title><source>JCR J. Clin. Rheumatol.</source><year>2021</year><volume>27</volume><fpage>e111</fpage><lpage>e112</lpage><pub-id pub-id-type="doi">10.1097/RHU.0000000000001287</pub-id><pub-id pub-id-type="pmid">31972742</pub-id>
</element-citation></ref><ref id="B14-dermatopathology-12-00007"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Lian</surname><given-names>H.</given-names></name>
<name><surname>Ma</surname><given-names>H.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>R.</given-names></name>
</person-group><article-title>Hemophagocytic Lymphohistiocytosis Associated with Histiocytic Necrotizing Lymphadenitis: A Clinical Study of 13 Children and Literature Review</article-title><source>J. Pediatr.</source><year>2021</year><volume>229</volume><fpage>267</fpage><lpage>274.e3</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2020.08.063</pub-id><pub-id pub-id-type="pmid">32956695</pub-id>
</element-citation></ref><ref id="B15-dermatopathology-12-00007"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takahashi</surname><given-names>K.</given-names></name>
<name><surname>Okura</surname><given-names>Y.</given-names></name>
<name><surname>Shimomura</surname><given-names>M.</given-names></name>
<name><surname>Taniguchi</surname><given-names>K.</given-names></name>
<name><surname>Nawate</surname><given-names>M.</given-names></name>
<name><surname>Takahashi</surname><given-names>Y.</given-names></name>
<name><surname>Kobayashi</surname><given-names>I.</given-names></name>
</person-group><article-title>Development of Sj&#x000f6;gren&#x02019;s syndrome following Kikuchi-Fujimoto disease&#x02014;A sibling case</article-title><source>Pediatr. Int.</source><year>2023</year><volume>65</volume><fpage>e15524</fpage><pub-id pub-id-type="doi">10.1111/ped.15524</pub-id><pub-id pub-id-type="pmid">36897118</pub-id>
</element-citation></ref><ref id="B16-dermatopathology-12-00007"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harrison</surname><given-names>J.</given-names></name>
<name><surname>Sukumaran</surname><given-names>S.</given-names></name>
<name><surname>Vijayan</surname><given-names>V.</given-names></name>
</person-group><article-title>Systemic Lupus Erythematosus Lymphadenopathy Presenting as Kikuchi-Fujimoto Disease in an Adolescent</article-title><source>Cureus</source><year>2023</year><volume>15</volume><fpage>e35304</fpage><pub-id pub-id-type="doi">10.7759/cureus.35304</pub-id><pub-id pub-id-type="pmid">36968890</pub-id>
</element-citation></ref><ref id="B17-dermatopathology-12-00007"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Choi</surname><given-names>S.</given-names></name>
<name><surname>Choi</surname><given-names>H.S.</given-names></name>
<name><surname>Ryu</surname><given-names>Y.J.</given-names></name>
<name><surname>Kim</surname><given-names>J.Y.</given-names></name>
<name><surname>Paik</surname><given-names>J.H.</given-names></name>
<name><surname>Ahn</surname><given-names>S.</given-names></name>
<name><surname>Lee</surname><given-names>H.</given-names></name>
</person-group><article-title>Characterization of Kikuchi-Fujimoto Disease in Children and Risk Factors Associated with Its Course</article-title><source>J. Pediatr.</source><year>2023</year><volume>260</volume><fpage>113515</fpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2023.113515</pub-id><pub-id pub-id-type="pmid">37244579</pub-id>
</element-citation></ref><ref id="B18-dermatopathology-12-00007"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martins</surname><given-names>S.S.</given-names></name>
<name><surname>Buscatti</surname><given-names>I.M.</given-names></name>
<name><surname>Freire</surname><given-names>P.S.</given-names></name>
<name><surname>Cavalcante</surname><given-names>E.G.</given-names></name>
<name><surname>Sallum</surname><given-names>A.M.</given-names></name>
<name><surname>Campos</surname><given-names>L.M.A.</given-names></name>
<name><surname>Silva</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto disease prior to childhood-systemic lupus erythematosus diagnosis</article-title><source>Rev. Bras. Reumatol.</source><year>2014</year><volume>54</volume><fpage>400</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1016/j.rbr.2013.03.003</pub-id><pub-id pub-id-type="pmid">25627306</pub-id>
</element-citation></ref><ref id="B19-dermatopathology-12-00007"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>Y.-C.</given-names></name>
<name><surname>Huang</surname><given-names>H.-H.</given-names></name>
<name><surname>Nong</surname><given-names>B.-R.</given-names></name>
<name><surname>Liu</surname><given-names>P.-Y.</given-names></name>
<name><surname>Chen</surname><given-names>Y.-Y.</given-names></name>
<name><surname>Huang</surname><given-names>Y.-F.</given-names></name>
<name><surname>Chiou</surname><given-names>Y.-H.</given-names></name>
<name><surname>Lee</surname><given-names>H.-S.</given-names></name>
</person-group><article-title>Pediatric Kikuchi-Fujimoto disease: A clinicopathologic study and the therapeutic effects of hydroxychloroquine</article-title><source>J. Microbiol. Immunol. Infect.</source><year>2019</year><volume>52</volume><fpage>395</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1016/j.jmii.2017.08.023</pub-id><pub-id pub-id-type="pmid">29050748</pub-id>
</element-citation></ref><ref id="B20-dermatopathology-12-00007"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Camacho-Badilla</surname><given-names>K.</given-names></name>
<name><surname>Ca&#x000f1;as-Coto</surname><given-names>A.</given-names></name>
<name><surname>Soriano-Fallas</surname><given-names>A.</given-names></name>
<name><surname>Carranza-Portocarrero</surname><given-names>A.</given-names></name>
<name><surname>Avila-Ag&#x000fc;ero</surname><given-names>M.L.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto disease in pediatric population: A case report and a review of literature</article-title><source>Gac. Med. Mex.</source><year>2005</year><volume>141</volume><fpage>53</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">15754752</pub-id>
</element-citation></ref><ref id="B21-dermatopathology-12-00007"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heldenberg</surname><given-names>D.</given-names></name>
<name><surname>Amar</surname><given-names>M.</given-names></name>
<name><surname>Ben-Arie</surname><given-names>Y.</given-names></name>
<name><surname>Iuchtman</surname><given-names>M.</given-names></name>
</person-group><article-title>Axillary involvement in pediatric Kikuchi&#x02019;s disease</article-title><source>Eur. J. Pediatr. Surg.</source><year>1996</year><volume>6</volume><fpage>32</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1055/s-2008-1066464</pub-id></element-citation></ref><ref id="B22-dermatopathology-12-00007"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chiang</surname><given-names>Y.-C.</given-names></name>
<name><surname>Chen</surname><given-names>R.M.Y.</given-names></name>
<name><surname>Chao</surname><given-names>P.-Z.</given-names></name>
<name><surname>Yang</surname><given-names>T.-H.</given-names></name>
<name><surname>Lee</surname><given-names>F.-P.</given-names></name>
</person-group><article-title>Pediatric Kikuchi-Fujimoto disease masquerading as a submandibular gland tumor</article-title><source>Int. J. Pediatr. Otorhinolaryngol.</source><year>2004</year><volume>68</volume><fpage>971</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1016/j.ijporl.2004.02.006</pub-id><pub-id pub-id-type="pmid">15183591</pub-id>
</element-citation></ref><ref id="B23-dermatopathology-12-00007"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lelii</surname><given-names>M.</given-names></name>
<name><surname>Senatore</surname><given-names>L.</given-names></name>
<name><surname>Amodeo</surname><given-names>I.</given-names></name>
<name><surname>Pinzani</surname><given-names>R.</given-names></name>
<name><surname>Torretta</surname><given-names>S.</given-names></name>
<name><surname>Fiori</surname><given-names>S.</given-names></name>
<name><surname>Marchisio</surname><given-names>P.</given-names></name>
<name><surname>Bosis</surname><given-names>S.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto disease in children: Two case reports and a review of the literature</article-title><source>Ital. J. Pediatr.</source><year>2018</year><volume>44</volume><fpage>83</fpage><pub-id pub-id-type="doi">10.1186/s13052-018-0522-9</pub-id><pub-id pub-id-type="pmid">30021595</pub-id>
</element-citation></ref><ref id="B24-dermatopathology-12-00007"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>J.M.</given-names></name>
<name><surname>Shermetaro</surname><given-names>C.B.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto Disease in Michigan: A Rare Case Report and Review of the Literature</article-title><source>Clin. Med. Insights Ear Nose Throat</source><year>2019</year><volume>12</volume><fpage>1179550619828680</fpage><pub-id pub-id-type="doi">10.1177/1179550619828680</pub-id><pub-id pub-id-type="pmid">30833818</pub-id>
</element-citation></ref><ref id="B25-dermatopathology-12-00007"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quadir</surname><given-names>A.</given-names></name>
<name><surname>Peacock</surname><given-names>K.</given-names></name>
<name><surname>Hsu</surname><given-names>P.</given-names></name>
<name><surname>Singh-Grewal</surname><given-names>D.</given-names></name>
<name><surname>Alexander</surname><given-names>S.</given-names></name>
</person-group><article-title>A familial case of Kikuchi-Fujimoto disease in dizygotic twins</article-title><source>Pediatr. Rheumatol. Online J.</source><year>2020</year><volume>18</volume><fpage>62</fpage><pub-id pub-id-type="doi">10.1186/s12969-020-00457-2</pub-id><pub-id pub-id-type="pmid">32778173</pub-id>
</element-citation></ref><ref id="B26-dermatopathology-12-00007"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>L.</given-names></name>
<name><surname>Tatarina-Numlan</surname><given-names>O.</given-names></name>
<name><surname>Yin</surname><given-names>Y.D.</given-names></name>
<name><surname>John</surname><given-names>M.</given-names></name>
<name><surname>Sundaram</surname><given-names>R.</given-names></name>
</person-group><article-title>A Case of Kikuchi-Fujimoto Disease in a 7-Year-Old African American Patient: A Case Report and Review of Literature</article-title><source>Am. J. Case Rep.</source><year>2020</year><volume>21</volume><fpage>e922784</fpage><pub-id pub-id-type="doi">10.12659/AJCR.922784</pub-id><pub-id pub-id-type="pmid">32830793</pub-id>
</element-citation></ref><ref id="B27-dermatopathology-12-00007"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cannon</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>E.</given-names></name>
<name><surname>Becker</surname><given-names>M.</given-names></name>
</person-group><article-title>Diagnosis of Kikuchi-Fujimoto disease in an 11-year-old girl with fever and sickle cell disease</article-title><source>BMJ Case Rep.</source><year>2020</year><volume>13</volume><fpage>e234302</fpage><pub-id pub-id-type="doi">10.1136/bcr-2020-234302</pub-id></element-citation></ref><ref id="B28-dermatopathology-12-00007"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chisholm</surname><given-names>K.M.</given-names></name>
<name><surname>Bohling</surname><given-names>S.D.</given-names></name>
<name><surname>Tsuchiya</surname><given-names>K.D.</given-names></name>
<name><surname>Paulson</surname><given-names>V.A.</given-names></name>
</person-group><article-title>A Malignant Mimicker: Features of Kikuchi-Fujimoto Disease in the Pediatric Population</article-title><source>Pediatr. Dev. Pathol.</source><year>2022</year><volume>25</volume><fpage>538</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1177/10935266221103882</pub-id><pub-id pub-id-type="pmid">35583198</pub-id>
</element-citation></ref><ref id="B29-dermatopathology-12-00007"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burns</surname><given-names>J.</given-names></name>
<name><surname>Pathania</surname><given-names>S.</given-names></name>
<name><surname>Griesser</surname><given-names>R.</given-names></name>
<name><surname>Norelli</surname><given-names>J.</given-names></name>
<name><surname>Gilgeours</surname><given-names>K.</given-names></name>
<name><surname>Tugetman</surname><given-names>J.</given-names></name>
<name><surname>Palumbo</surname><given-names>N.</given-names></name>
</person-group><article-title>Evaluation of a unilateral neck mass in a 16-year-old female: Kikuchi-Fujimoto disease with superimposed bacterial lymphadenitis</article-title><source>SAGE Open Med. Case Rep.</source><year>2020</year><volume>8</volume><fpage>2050313X20962640</fpage><pub-id pub-id-type="doi">10.1177/2050313X20962640</pub-id></element-citation></ref><ref id="B30-dermatopathology-12-00007"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>H.S.</given-names></name>
<name><surname>Sung</surname><given-names>M.J.</given-names></name>
<name><surname>Park</surname><given-names>S.E.</given-names></name>
<name><surname>Lim</surname><given-names>Y.T.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto disease of 16 children in a single center of Korea</article-title><source>Pediatr. Allergy Immunol.</source><year>2007</year><volume>18</volume><fpage>174</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1111/j.1399-3038.2006.00505.x</pub-id><pub-id pub-id-type="pmid">17338792</pub-id>
</element-citation></ref><ref id="B31-dermatopathology-12-00007"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>G&#x000f3;mez</surname><given-names>C.</given-names></name>
<name><surname>Eraso</surname><given-names>R.M.</given-names></name>
<name><surname>Aguirre</surname><given-names>C.A.</given-names></name>
<name><surname>P&#x000e9;rez</surname><given-names>M.D.P.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto disease: Pediatric case presentation</article-title><source>Biomedica</source><year>2010</year><volume>30</volume><fpage>465</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.7705/biomedica.v30i4.283</pub-id><pub-id pub-id-type="pmid">21713349</pub-id>
</element-citation></ref><ref id="B32-dermatopathology-12-00007"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ojeda Lewis</surname><given-names>E.</given-names></name>
<name><surname>V&#x000e1;squez Paz</surname><given-names>H.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto disease: Pediatric case report</article-title><source>Medwave</source><year>2015</year><volume>15</volume><fpage>e6270</fpage><pub-id pub-id-type="doi">10.5867/medwave.2015.08.6270</pub-id><pub-id pub-id-type="pmid">26485619</pub-id>
</element-citation></ref><ref id="B33-dermatopathology-12-00007"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>J.S.</given-names></name>
<name><surname>Chang</surname><given-names>K.C.</given-names></name>
<name><surname>Cheng</surname><given-names>C.N.</given-names></name>
<name><surname>Tsai</surname><given-names>W.H.</given-names></name>
<name><surname>Su</surname><given-names>I.J.</given-names></name>
</person-group><article-title>Childhood hemophagocytic syndrome associated with Kikuchi&#x02019;s disease</article-title><source>Haematologica</source><year>2000</year><volume>85</volume><fpage>998</fpage><lpage>1000</lpage><pub-id pub-id-type="pmid">10980648</pub-id>
</element-citation></ref><ref id="B34-dermatopathology-12-00007"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jun-Fen</surname><given-names>F.</given-names></name>
<name><surname>Chun-Lin</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Dayan</surname><given-names>C.</given-names></name>
<name><surname>Guan-Ping</surname><given-names>D.</given-names></name>
<name><surname>Fang</surname><given-names>H.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto disease manifesting as recurrent thrombocytopenia and Mobitz type II atrioventricular block in a 7-year-old girl: A case report and analysis of 138 Chinese childhood Kikuchi-Fujimoto cases with 10 years of follow-up in 97 patients</article-title><source>Acta Paediatr.</source><year>2007</year><volume>96</volume><fpage>1844</fpage><lpage>1847</lpage><pub-id pub-id-type="doi">10.1111/j.1651-2227.2007.00523.x</pub-id><pub-id pub-id-type="pmid">17931395</pub-id>
</element-citation></ref><ref id="B35-dermatopathology-12-00007"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Altinel A&#x000e7;o&#x0011f;lu</surname><given-names>E.</given-names></name>
<name><surname>Sari</surname><given-names>E.</given-names></name>
<name><surname>&#x0015e;ahin</surname><given-names>G.</given-names></name>
<name><surname>O&#x0011f;uz</surname><given-names>M.M.</given-names></name>
<name><surname>Ak&#x000e7;aboy</surname><given-names>M.</given-names></name>
<name><surname>Zorlu</surname><given-names>P.</given-names></name>
<name><surname>Senel</surname><given-names>S.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto disease triggered by Salmonella enteritidis in a child with concurrent auto-immune thyroiditis and papilloedema</article-title><source>Paediatr. Int. Child Health</source><year>2018</year><volume>38</volume><fpage>298</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1080/20469047.2017.1420523</pub-id><pub-id pub-id-type="pmid">29307273</pub-id>
</element-citation></ref><ref id="B36-dermatopathology-12-00007"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bao</surname><given-names>S.</given-names></name>
<name><surname>Huang</surname><given-names>H.</given-names></name>
<name><surname>Jin</surname><given-names>Y.</given-names></name>
<name><surname>Ding</surname><given-names>F.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Han</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Lu</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Optic Neuritis in a Pediatric Patient with Kikuchi-Fujimoto Disease: A Case Report and Review of the Literature</article-title><source>J. Inflamm. Res.</source><year>2024</year><volume>17</volume><fpage>2889</fpage><lpage>2895</lpage><pub-id pub-id-type="doi">10.2147/JIR.S458990</pub-id><pub-id pub-id-type="pmid">38751686</pub-id>
</element-citation></ref><ref id="B37-dermatopathology-12-00007"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guleria</surname><given-names>S.</given-names></name>
<name><surname>Gupta</surname><given-names>A.</given-names></name>
<name><surname>Pilania</surname><given-names>R.K.</given-names></name>
<name><surname>Pandiarajan</surname><given-names>V.</given-names></name>
<name><surname>Rawat</surname><given-names>A.</given-names></name>
<name><surname>Saikia</surname><given-names>U.N.</given-names></name>
<name><surname>Singh</surname><given-names>S.</given-names></name>
<name><surname>Suri</surname><given-names>D.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto Disease: An Under Recognized Cause of Fever with Lymphadenopathy</article-title><source>Indian J. Pediatr.</source><year>2020</year><volume>87</volume><fpage>85</fpage><pub-id pub-id-type="doi">10.1007/s12098-019-03070-8</pub-id><pub-id pub-id-type="pmid">31520311</pub-id>
</element-citation></ref><ref id="B38-dermatopathology-12-00007"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hua</surname><given-names>C.-Z.</given-names></name>
<name><surname>Chen</surname><given-names>Y.-K.</given-names></name>
<name><surname>Chen</surname><given-names>S.-Z.</given-names></name>
<name><surname>Gu</surname><given-names>W.-Z.</given-names></name>
<name><surname>Shu</surname><given-names>Q.</given-names></name>
</person-group><article-title>Histiocytic Necrotizing Lymphadenitis Mimicking Acute Appendicitis in a Child: A Case Report</article-title><source>Front. Pediatr.</source><year>2021</year><volume>9</volume><elocation-id>682738</elocation-id><pub-id pub-id-type="doi">10.3389/fped.2021.682738</pub-id><pub-id pub-id-type="pmid">34604132</pub-id>
</element-citation></ref><ref id="B39-dermatopathology-12-00007"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chowdhury</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Extra-nodal Kikuchi Disease and Kikuchi Encephalitis</article-title><source>Indian Pediatr.</source><year>2019</year><volume>56</volume><fpage>881</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1007/s13312-019-1620-5</pub-id><pub-id pub-id-type="pmid">31724549</pub-id>
</element-citation></ref><ref id="B40-dermatopathology-12-00007"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gon&#x000e7;alves</surname><given-names>L.F.</given-names></name>
<name><surname>Debelenko</surname><given-names>L.V.</given-names></name>
<name><surname>Bhambhani</surname><given-names>K.J.</given-names></name>
<name><surname>Scheid</surname><given-names>A.</given-names></name>
<name><surname>Altinok</surname><given-names>D.</given-names></name>
</person-group><article-title>Histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto disease) with CNS involvement in a child</article-title><source>Pediatr. Radiol.</source><year>2014</year><volume>44</volume><fpage>234</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1007/s00247-013-2786-y</pub-id><pub-id pub-id-type="pmid">24091923</pub-id>
</element-citation></ref><ref id="B41-dermatopathology-12-00007"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sykes</surname><given-names>J.A.</given-names></name>
<name><surname>Badizadegan</surname><given-names>K.</given-names></name>
<name><surname>Gordon</surname><given-names>P.</given-names></name>
<name><surname>Sokol</surname><given-names>D.</given-names></name>
<name><surname>Escoto</surname><given-names>M.</given-names></name>
<name><surname>Ten</surname><given-names>I.</given-names></name>
<name><surname>Vyas</surname><given-names>S.</given-names></name>
<name><surname>Torres</surname><given-names>A.</given-names></name>
<name><surname>Levine</surname><given-names>A.-M.</given-names></name>
</person-group><article-title>Simultaneous Acquired Self-limited Hemophagocytic Lymphohistiocytosis and Kikuchi Necrotizing Lymphadenitis in a 16-Year-Old Teenage Girl: A Case Report and Review of the Literature</article-title><source>Pediatr. Emerg. Care</source><year>2016</year><volume>32</volume><fpage>792</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1097/PEC.0000000000000560</pub-id><pub-id pub-id-type="pmid">26555310</pub-id>
</element-citation></ref><ref id="B42-dermatopathology-12-00007"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Emir</surname><given-names>S.</given-names></name>
<name><surname>G&#x000f6;g&#x000fc;&#x0015f;</surname><given-names>S.</given-names></name>
<name><surname>G&#x000fc;ler</surname><given-names>E.</given-names></name>
<name><surname>B&#x000fc;y&#x000fc;kpamuk&#x000e7;u</surname><given-names>M.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto disease (histiocytic necrotizing lymphadenitis) confused with lymphoma in a child</article-title><source>Med. Pediatr. Oncol.</source><year>2001</year><volume>37</volume><fpage>546</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1002/mpo.1251</pub-id><pub-id pub-id-type="pmid">11745896</pub-id>
</element-citation></ref><ref id="B43-dermatopathology-12-00007"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tchidjou</surname><given-names>H.K.</given-names></name>
<name><surname>Macchiaiolo</surname><given-names>M.</given-names></name>
<name><surname>Ariganello</surname><given-names>P.</given-names></name>
<name><surname>Carducci</surname><given-names>F.C.</given-names></name>
<name><surname>De Vito</surname><given-names>R.</given-names></name>
<name><surname>De Benedetti</surname><given-names>F.</given-names></name>
<name><surname>D&#x02019;argenio</surname><given-names>P.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto disease in patient with systemic phacomatosis pigmentovascularis</article-title><source>Blood Coagul. Fibrinolysis</source><year>2014</year><volume>25</volume><fpage>783</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1097/MBC.0000000000000129</pub-id><pub-id pub-id-type="pmid">25251688</pub-id>
</element-citation></ref><ref id="B44-dermatopathology-12-00007"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rossetti</surname><given-names>E.</given-names></name>
<name><surname>Appierto</surname><given-names>L.</given-names></name>
<name><surname>Bianchi</surname><given-names>R.</given-names></name>
<name><surname>Picardo</surname><given-names>S.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto disease and life-threatening upper airway obstruction</article-title><source>Paediatr. Anaesth.</source><year>2015</year><volume>25</volume><fpage>864</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1111/pan.12703</pub-id><pub-id pub-id-type="pmid">26149772</pub-id>
</element-citation></ref><ref id="B45-dermatopathology-12-00007"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Handa</surname><given-names>A.</given-names></name>
<name><surname>Nozaki</surname><given-names>T.</given-names></name>
<name><surname>Hosoya</surname><given-names>Y.</given-names></name>
<name><surname>Sakoda</surname><given-names>A.</given-names></name>
<name><surname>Suzuki</surname><given-names>K.</given-names></name>
</person-group><article-title>Multiple migratory recurrence of Kikuchi-Fujimoto disease</article-title><source>Pediatr. Int.</source><year>2016</year><volume>58</volume><fpage>1360</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1111/ped.13048</pub-id><pub-id pub-id-type="pmid">28008733</pub-id>
</element-citation></ref><ref id="B46-dermatopathology-12-00007"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arslan</surname><given-names>A.</given-names></name>
<name><surname>Kraus</surname><given-names>C.L.</given-names></name>
<name><surname>Izbudak</surname><given-names>I.</given-names></name>
</person-group><article-title>Optic Neuritis as an Isolated Presentation of Kikuchi&#x02013;Fujimoto Disease in a Pediatric Patient</article-title><source>Balk. Med. J.</source><year>2020</year><volume>37</volume><fpage>172</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.4274/balkanmedj.galenos.2019.2019.11.88</pub-id><pub-id pub-id-type="pmid">31876134</pub-id>
</element-citation></ref><ref id="B47-dermatopathology-12-00007"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x000d6;zt&#x000fc;rk</surname><given-names>N.</given-names></name>
<name><surname>K&#x00131;l&#x00131;&#x000e7;</surname><given-names>&#x00130;.</given-names></name>
<name><surname>G&#x000f6;&#x000e7;&#x000fc;n</surname><given-names>P.U.</given-names></name>
<name><surname>Kaya</surname><given-names>Z.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto disease in a child who had a high suspicion of COVID-19 infection</article-title><source>J. Hematop.</source><year>2022</year><volume>15</volume><fpage>197</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1007/s12308-022-00501-y</pub-id><pub-id pub-id-type="pmid">35669856</pub-id>
</element-citation></ref><ref id="B48-dermatopathology-12-00007"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sevrin</surname><given-names>F.</given-names></name>
<name><surname>Beaujot</surname><given-names>J.</given-names></name>
<name><surname>Jaillard</surname><given-names>A.</given-names></name>
<name><surname>Fayard</surname><given-names>C.</given-names></name>
<name><surname>Forestier</surname><given-names>A.</given-names></name>
<name><surname>Defachelles</surname><given-names>A.-S.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto disease following SARS-CoV-2 vaccination in a patient with previous history of rhabdomyosarcoma</article-title><source>Pediatr. Blood Cancer</source><year>2023</year><volume>70</volume><fpage>e30345</fpage><pub-id pub-id-type="doi">10.1002/pbc.30345</pub-id><pub-id pub-id-type="pmid">37073625</pub-id>
</element-citation></ref><ref id="B49-dermatopathology-12-00007"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Shu</surname><given-names>S.</given-names></name>
</person-group><article-title>Histiocytic necrotizing lymphadenitis with autoimmune encephalitis in a child: A case report</article-title><source>Transl. Pediatr.</source><year>2024</year><volume>13</volume><fpage>1892</fpage><lpage>1898</lpage><pub-id pub-id-type="doi">10.21037/tp-24-380</pub-id><pub-id pub-id-type="pmid">39524397</pub-id>
</element-citation></ref><ref id="B50-dermatopathology-12-00007"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>E.S.</given-names></name>
<name><surname>Hoyek</surname><given-names>S.</given-names></name>
<name><surname>Yuan</surname><given-names>M.</given-names></name>
<name><surname>El Khatib</surname><given-names>B.A.</given-names></name>
<name><surname>Gonzalez</surname><given-names>E.</given-names></name>
<name><surname>Rothermel</surname><given-names>H.</given-names></name>
<name><surname>Gise</surname><given-names>R.</given-names></name>
<name><surname>Patel</surname><given-names>N.A.</given-names></name>
</person-group><article-title>Occlusive Retinal Vasculitis in a Pediatric Patient with Kikuchi-Fujimoto Disease and Sickle Cell Trait</article-title><source>Ophthalmic Surg. Lasers Imaging Retin.</source><year>2024</year><volume>55</volume><fpage>235</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.3928/23258160-20240123-01</pub-id><pub-id pub-id-type="pmid">38319054</pub-id>
</element-citation></ref><ref id="B51-dermatopathology-12-00007"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Das</surname><given-names>A.</given-names></name>
<name><surname>Bhave</surname><given-names>S.J.</given-names></name>
<name><surname>Pal</surname><given-names>B.</given-names></name>
<name><surname>Arun</surname><given-names>I.</given-names></name>
<name><surname>Goel</surname><given-names>G.</given-names></name>
<name><surname>Bhattacharya</surname><given-names>S.</given-names></name>
<name><surname>Sen</surname><given-names>S.</given-names></name>
<name><surname>Das</surname><given-names>J.</given-names></name>
<name><surname>Bhattacharyya</surname><given-names>P.</given-names></name>
</person-group><article-title>Brucellosis Complicated by Kikuchi-Fujimoto Disease and Doxycycline-Induced Intracranial Hypertension</article-title><source>Indian J. Pediatr.</source><year>2019</year><volume>86</volume><fpage>1063</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1007/s12098-019-02937-0</pub-id><pub-id pub-id-type="pmid">30945234</pub-id>
</element-citation></ref><ref id="B52-dermatopathology-12-00007"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdu</surname><given-names>A.</given-names></name>
<name><surname>Pajkrt</surname><given-names>D.</given-names></name>
<name><surname>Bijker</surname><given-names>E.M.</given-names></name>
</person-group><article-title>Kikuchi Disease in Children: Case Report and Review of the Literature</article-title><source>Pediatr. Infect. Dis. J.</source><year>2022</year><volume>41</volume><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000003397</pub-id><pub-id pub-id-type="pmid">34862340</pub-id>
</element-citation></ref><ref id="B53-dermatopathology-12-00007"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seo</surname><given-names>J.-H.</given-names></name>
<name><surname>Lee</surname><given-names>J.S.</given-names></name>
<name><surname>Lee</surname><given-names>E.-J.</given-names></name>
<name><surname>Lee</surname><given-names>J.-H.</given-names></name>
<name><surname>Kim</surname><given-names>J.P.</given-names></name>
<name><surname>Woo</surname><given-names>S.H.</given-names></name>
<name><surname>Ahn</surname><given-names>S.-K.</given-names></name>
<name><surname>Kwon</surname><given-names>O.J.</given-names></name>
<name><surname>Hwa</surname><given-names>J.S.</given-names></name>
<name><surname>Park</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Comparison of clinical features and EBV expression in histiocytic necrotizing lymphadenitis of children and adults</article-title><source>Int. J. Pediatr. Otorhinolaryngol.</source><year>2014</year><volume>78</volume><fpage>748</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1016/j.ijporl.2014.02.001</pub-id><pub-id pub-id-type="pmid">24594231</pub-id>
</element-citation></ref><ref id="B54-dermatopathology-12-00007"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yen</surname><given-names>H.-R.</given-names></name>
<name><surname>Lin</surname><given-names>P.-Y.</given-names></name>
<name><surname>Chuang</surname><given-names>W.-Y.</given-names></name>
<name><surname>Chang</surname><given-names>M.-L.</given-names></name>
<name><surname>Chiu</surname><given-names>C.-H.</given-names></name>
</person-group><article-title>Skin manifestations of Kikuchi-Fujimoto disease: Case report and review</article-title><source>Eur. J. Pediatr.</source><year>2004</year><volume>163</volume><fpage>210</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1007/s00431-003-1364-y</pub-id><pub-id pub-id-type="pmid">14986121</pub-id>
</element-citation></ref><ref id="B55-dermatopathology-12-00007"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yasukawa</surname><given-names>K.</given-names></name>
<name><surname>Matsumura</surname><given-names>T.</given-names></name>
<name><surname>Sato-Matsumura</surname><given-names>K.C.</given-names></name>
<name><surname>Takahashi</surname><given-names>T.</given-names></name>
<name><surname>Fujioka</surname><given-names>Y.</given-names></name>
<name><surname>Kobayashi</surname><given-names>H.</given-names></name>
<name><surname>Shimizu</surname><given-names>H.</given-names></name>
</person-group><article-title>Kikuchi&#x02019;s disease and the skin: Case report and review of the literature</article-title><source>Br. J. Dermatol.</source><year>2001</year><volume>144</volume><fpage>885</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2133.2001.04151.x</pub-id><pub-id pub-id-type="pmid">11298555</pub-id>
</element-citation></ref><ref id="B56-dermatopathology-12-00007"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>K.J.</given-names></name>
<name><surname>Jee</surname><given-names>M.S.</given-names></name>
<name><surname>Chang</surname><given-names>S.E.</given-names></name>
<name><surname>Choi</surname><given-names>J.H.</given-names></name>
<name><surname>Sung</surname><given-names>K.J.</given-names></name>
<name><surname>Moon</surname><given-names>K.C.</given-names></name>
<name><surname>Koh</surname><given-names>J.K.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto disease with papulopustular skin manifestations</article-title><source>Clin. Exp. Dermatol.</source><year>2003</year><volume>28</volume><fpage>142</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2230.2003.01160.x</pub-id><pub-id pub-id-type="pmid">12653698</pub-id>
</element-citation></ref><ref id="B57-dermatopathology-12-00007"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>J.H.</given-names></name>
<name><surname>Kim</surname><given-names>Y.B.</given-names></name>
<name><surname>In SIl Kim</surname><given-names>Y.C.</given-names></name>
<name><surname>Han</surname><given-names>J.H.</given-names></name>
</person-group><article-title>The cutaneous lesions of Kikuchi&#x02019;s disease: A comprehensive analysis of 16 cases based on the clinicopathologic, immunohistochemical, and immunofluorescence studies with an emphasis on the differential diagnosis</article-title><source>Hum. Pathol.</source><year>2010</year><volume>41</volume><fpage>1245</fpage><lpage>1254</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2010.02.002</pub-id><pub-id pub-id-type="pmid">20434191</pub-id>
</element-citation></ref><ref id="B58-dermatopathology-12-00007"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spies</surname><given-names>J.</given-names></name>
<name><surname>Foucar</surname><given-names>K.</given-names></name>
<name><surname>Thompson</surname><given-names>C.T.</given-names></name>
<name><surname>LeBoit</surname><given-names>P.E.</given-names></name>
</person-group><article-title>The histopathology of cutaneous lesions of Kikuchi&#x02019;s disease (necrotizing lymphadenitis): A report of five cases</article-title><source>Am. J. Surg. Pathol.</source><year>1999</year><volume>23</volume><fpage>1040</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1097/00000478-199909000-00006</pub-id><pub-id pub-id-type="pmid">10478663</pub-id>
</element-citation></ref><ref id="B59-dermatopathology-12-00007"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paradela</surname><given-names>S.</given-names></name>
<name><surname>Lorenzo</surname><given-names>J.</given-names></name>
<name><surname>Mart&#x000ed;nez-G&#x000f3;mez</surname><given-names>W.</given-names></name>
<name><surname>Yebra-Pimentel</surname><given-names>T.</given-names></name>
<name><surname>Valbuena</surname><given-names>L.</given-names></name>
<name><surname>Fonseca</surname><given-names>E.</given-names></name>
</person-group><article-title>Interface dermatitis in skin lesions of Kikuchi-Fujimoto&#x02019;s disease: A histopathological marker of evolution into systemic lupus erythematosus?</article-title><source>Lupus</source><year>2008</year><volume>17</volume><fpage>1127</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1177/0961203308092161</pub-id><pub-id pub-id-type="pmid">19029282</pub-id>
</element-citation></ref><ref id="B60-dermatopathology-12-00007"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frankel</surname><given-names>A.M.</given-names></name>
<name><surname>Frenkel</surname><given-names>S.</given-names></name>
<name><surname>Aminlari</surname><given-names>A.</given-names></name>
<name><surname>Chan</surname><given-names>T.</given-names></name>
</person-group><article-title>Kikuchi Disease: A Case Report</article-title><source>J. Emerg. Med.</source><year>2020</year><volume>59</volume><fpage>927</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1016/j.jemermed.2020.07.031</pub-id><pub-id pub-id-type="pmid">32921539</pub-id>
</element-citation></ref><ref id="B61-dermatopathology-12-00007"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yen</surname><given-names>A.</given-names></name>
<name><surname>Fearneyhough</surname><given-names>P.</given-names></name>
<name><surname>Raimer</surname><given-names>S.S.</given-names></name>
<name><surname>Hudnall</surname><given-names>S.D.</given-names></name>
</person-group><article-title>EBV-associated Kikuchi&#x02019;s histiocytic necrotizing lymphadenitis with cutaneous manifestations</article-title><source>J. Am. Acad. Dermatol.</source><year>1997</year><volume>36</volume><fpage>342</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1016/S0190-9622(97)80413-6</pub-id><pub-id pub-id-type="pmid">9039215</pub-id>
</element-citation></ref><ref id="B62-dermatopathology-12-00007"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuo</surname><given-names>T.T.</given-names></name>
</person-group><article-title>Kikuchi&#x02019;s disease (histiocytic necrotizing lymphadenitis). A clinicopathologic study of 79 cases with an analysis of histologic subtypes, immunohistology, and DNA ploidy</article-title><source>Am. J. Surg. Pathol.</source><year>1995</year><volume>19</volume><fpage>798</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1097/00000478-199507000-00008</pub-id><pub-id pub-id-type="pmid">7793478</pub-id>
</element-citation></ref><ref id="B63-dermatopathology-12-00007"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>R.-B.</given-names></name>
<name><surname>Chen</surname><given-names>Y.-J.</given-names></name>
<name><surname>Chang</surname><given-names>C.-H.</given-names></name>
<name><surname>Chen</surname><given-names>Y.-L.</given-names></name>
<name><surname>Chen</surname><given-names>J.-W.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto Disease Associated with Mycoplasma Pneumoniae Infection</article-title><source>Ear Nose Throat J.</source><year>2024</year><volume>103</volume><fpage>NP223</fpage><lpage>NP225</lpage><pub-id pub-id-type="doi">10.1177/01455613211044225</pub-id><pub-id pub-id-type="pmid">34605286</pub-id>
</element-citation></ref><ref id="B64-dermatopathology-12-00007"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>M&#x000fc;ller</surname><given-names>C.S.L.</given-names></name>
<name><surname>Vogt</surname><given-names>T.</given-names></name>
<name><surname>Becker</surname><given-names>S.L.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto Disease Triggered by Systemic Lupus Erythematosus and Mycoplasma pneumoniae Infection-A Report of a Case and a Review of the Literature</article-title><source>Am. J. Dermatopathol.</source><year>2021</year><volume>43</volume><fpage>202</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1097/DAD.0000000000001764</pub-id><pub-id pub-id-type="pmid">32809980</pub-id>
</element-citation></ref><ref id="B65-dermatopathology-12-00007"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bosch</surname><given-names>X.</given-names></name>
<name><surname>Guilabert</surname><given-names>A.</given-names></name>
<name><surname>Miquel</surname><given-names>R.</given-names></name>
<name><surname>Campo</surname><given-names>E.</given-names></name>
</person-group><article-title>Enigmatic Kikuchi-Fujimoto disease: A comprehensive review</article-title><source>Am. J. Clin. Pathol.</source><year>2004</year><volume>122</volume><fpage>141</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1309/YF081L4TKYWVYVPQ</pub-id><pub-id pub-id-type="pmid">15272543</pub-id>
</element-citation></ref><ref id="B66-dermatopathology-12-00007"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pepe</surname><given-names>F.</given-names></name>
<name><surname>Disma</surname><given-names>S.</given-names></name>
<name><surname>Teodoro</surname><given-names>C.</given-names></name>
<name><surname>Pepe</surname><given-names>P.</given-names></name>
<name><surname>Magro</surname><given-names>G.</given-names></name>
</person-group><article-title>Kikuchi-Fujimoto disease: A clinicopathologic update</article-title><source>Pathologica</source><year>2016</year><volume>108</volume><fpage>120</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">28195263</pub-id>
</element-citation></ref><ref id="B67-dermatopathology-12-00007"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mehrian</surname><given-names>P.</given-names></name>
<name><surname>Doroudinia</surname><given-names>A.</given-names></name>
<name><surname>Shams</surname><given-names>M.</given-names></name>
<name><surname>Alizadeh</surname><given-names>N.</given-names></name>
</person-group><article-title>Distribution and Characteristics of Intrathoracic Lymphadenopathy in TB/HIV Co-Infection</article-title><source>Infect. Disord. Drug Targets</source><year>2019</year><volume>19</volume><fpage>414</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.2174/1871526518666181016111142</pub-id><pub-id pub-id-type="pmid">30324894</pub-id>
</element-citation></ref><ref id="B68-dermatopathology-12-00007"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Louissaint</surname><given-names>A.J.</given-names></name>
<name><surname>Ferry</surname><given-names>J.A.</given-names></name>
<name><surname>Soupir</surname><given-names>C.P.</given-names></name>
<name><surname>Hasserjian</surname><given-names>R.P.</given-names></name>
<name><surname>Harris</surname><given-names>N.L.</given-names></name>
<name><surname>Zukerberg</surname><given-names>L.R.</given-names></name>
</person-group><article-title>Infectious mononucleosis mimicking lymphoma: Distinguishing morphological and immunophenotypic features</article-title><source>Mod. Pathol.</source><year>2012</year><volume>25</volume><fpage>1149</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2012.70</pub-id><pub-id pub-id-type="pmid">22627742</pub-id>
</element-citation></ref><ref id="B69-dermatopathology-12-00007"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Almond</surname><given-names>L.M.</given-names></name>
<name><surname>Charalampakis</surname><given-names>M.</given-names></name>
<name><surname>Ford</surname><given-names>S.J.</given-names></name>
<name><surname>Gourevitch</surname><given-names>D.</given-names></name>
<name><surname>Desai</surname><given-names>A.</given-names></name>
</person-group><article-title>Myeloid Sarcoma: Presentation, Diagnosis, and Treatment</article-title><source>Clin. Lymphoma Myeloma Leuk.</source><year>2017</year><volume>17</volume><fpage>263</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1016/j.clml.2017.02.027</pub-id><pub-id pub-id-type="pmid">28342811</pub-id>
</element-citation></ref><ref id="B70-dermatopathology-12-00007"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bowers</surname><given-names>S.</given-names></name>
<name><surname>Warshaw</surname><given-names>E.M.</given-names></name>
</person-group><article-title>Pityriasis lichenoides and its subtypes</article-title><source>J. Am. Acad. Dermatol.</source><year>2006</year><volume>55</volume><fpage>556</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2005.07.058</pub-id><pub-id pub-id-type="pmid">17010734</pub-id>
</element-citation></ref><ref id="B71-dermatopathology-12-00007"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rashtak</surname><given-names>S.</given-names></name>
<name><surname>Pittelkow</surname><given-names>M.R.</given-names></name>
</person-group><article-title>Skin involvement in systemic autoimmune diseases</article-title><source>Curr. Dir. Autoimmun.</source><year>2008</year><volume>10</volume><fpage>344</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">18460895</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="dermatopathology-12-00007-f001"><label>Figure 1</label><caption><p>Cutaneous manifestations: (<bold>A</bold>) Onset of the cutaneous eruption, characterized by erosive lesions on erythematoedematous plaques distributed in the centrofacial area and auricular lobes. (<bold>B</bold>) Resolution of the erythematoedematous component, persistence of ulcers and crusts. (<bold>C</bold>) One week after hospital discharge, progressive remission and re-epithelialization of the erosions. (<bold>D</bold>) One month after hospital discharge, showing residual marks of the rash resembling varioliform scars.</p></caption><graphic xlink:href="dermatopathology-12-00007-g001" position="float"/></fig><fig position="float" id="dermatopathology-12-00007-f002"><label>Figure 2</label><caption><p>Lymph node biopsy: (<bold>A</bold>) Hematoxylin and eosin (H&#x00026;E) stain 20&#x000d7;: Normal lymphoid node population in the left half, with areas of paracortical necrosis. Extensive necrosis is observed in the right half. (<bold>B</bold>) H&#x00026;E 400&#x000d7;: Area of central necrosis lacking polymorphonuclear cells (asterisk), flanked by an infiltrate rich in immunoblasts, plasmacytoid dendritic cells, and histiocytes (arrowheads), without forming organized granulomas. Nuclear debris (white circles) is present within the necrotic area. (<bold>C</bold>) Immunohistochemistry (IHC) 100&#x000d7;: CD123 expression in plasmacytoid dendritic cells surrounding the areas of necrosis.</p></caption><graphic xlink:href="dermatopathology-12-00007-g002" position="float"/></fig><fig position="float" id="dermatopathology-12-00007-f003"><label>Figure 3</label><caption><p>Skin biopsy: (<bold>A</bold>) H&#x00026;E, 2&#x000d7;: superficial and mild lymphocytic perivascular dermatitis, lack of interface changes, adnexal trophism, mucin deposits or nuclear debris. (<bold>B</bold>) H&#x00026;E, 10&#x000d7;: lymphocytic infiltrate without peri adnexal involvement and no neutrophils present. (<bold>C</bold>) PAS stain, 20&#x000d7;: focal thickening of the basal layer. (<bold>D</bold>) PAS stain, 40&#x000d7;: mild spongiosis without vacuolar degeneration of basal cells.</p></caption><graphic xlink:href="dermatopathology-12-00007-g003" position="float"/></fig><fig position="float" id="dermatopathology-12-00007-f004"><label>Figure 4</label><caption><p>Research strategy and selected articles.</p></caption><graphic xlink:href="dermatopathology-12-00007-g004" position="float"/></fig></floats-group></article>